1
|
Manfredi-Lozano M, Leysen V, Adamo M, Paiva I, Rovera R, Pignat JM, Timzoura FE, Candlish M, Eddarkaoui S, Malone SA, Silva MSB, Trova S, Imbernon M, Decoster L, Cotellessa L, Tena-Sempere M, Claret M, Paoloni-Giacobino A, Plassard D, Paccou E, Vionnet N, Acierno J, Maceski AM, Lutti A, Pfrieger F, Rasika S, Santoni F, Boehm U, Ciofi P, Buée L, Haddjeri N, Boutillier AL, Kuhle J, Messina A, Draganski B, Giacobini P, Pitteloud N, Prevot V. GnRH replacement rescues cognition in Down syndrome. Science 2022; 377:eabq4515. [PMID: 36048943 PMCID: PMC7613827 DOI: 10.1126/science.abq4515] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
At the present time, no viable treatment exists for cognitive and olfactory deficits in Down syndrome (DS). We show in a DS model (Ts65Dn mice) that these progressive nonreproductive neurological symptoms closely parallel a postpubertal decrease in hypothalamic as well as extrahypothalamic expression of a master molecule that controls reproduction-gonadotropin-releasing hormone (GnRH)-and appear related to an imbalance in a microRNA-gene network known to regulate GnRH neuron maturation together with altered hippocampal synaptic transmission. Epigenetic, cellular, chemogenetic, and pharmacological interventions that restore physiological GnRH levels abolish olfactory and cognitive defects in Ts65Dn mice, whereas pulsatile GnRH therapy improves cognition and brain connectivity in adult DS patients. GnRH thus plays a crucial role in olfaction and cognition, and pulsatile GnRH therapy holds promise to improve cognitive deficits in DS.
Collapse
Affiliation(s)
- Maria Manfredi-Lozano
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S 1172, LabexDistAlz, Lille, France,Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 days for health, EGID, Lille, France
| | - Valerie Leysen
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S 1172, LabexDistAlz, Lille, France,Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 days for health, EGID, Lille, France
| | - Michela Adamo
- Department of Endocrinology, Diabetology, and Metabolism, Lausanne University Hospital, 1011 Lausanne, Switzerland,Faculty of Biology and Medicine, University of Lausanne, Lausanne 1005, Switzerland
| | - Isabel Paiva
- Laboratoire de Neurosciences Cognitives et Adaptatives (LNCA), UMR 7364, Université de Strasbourg-CNRS, Strasbourg, France
| | - Renaud Rovera
- Univ. Lyon, Université Claude Bernard Lyon 1, Inserm, Stem Cell and Brain Research Institute U1208, Bron 69500, France
| | - Jean-Michel Pignat
- Department of Clinical Neurosciences, Neurorehabilitation Unit, University Hospital CHUV, Lausanne, Switzerland
| | - Fatima Ezzahra Timzoura
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S 1172, LabexDistAlz, Lille, France,Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 days for health, EGID, Lille, France
| | - Michael Candlish
- Experimental Pharmacology, Center for Molecular Signaling (PZMS), Saarland University School of Medicine, 66421, Homburg, Germany
| | - Sabiha Eddarkaoui
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S 1172, LabexDistAlz, Lille, France
| | - Samuel A. Malone
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S 1172, LabexDistAlz, Lille, France,Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 days for health, EGID, Lille, France
| | - Mauro S. B. Silva
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S 1172, LabexDistAlz, Lille, France,Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 days for health, EGID, Lille, France
| | - Sara Trova
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S 1172, LabexDistAlz, Lille, France,Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 days for health, EGID, Lille, France
| | - Monica Imbernon
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S 1172, LabexDistAlz, Lille, France,Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 days for health, EGID, Lille, France
| | - Laurine Decoster
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S 1172, LabexDistAlz, Lille, France,Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 days for health, EGID, Lille, France
| | - Ludovica Cotellessa
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S 1172, LabexDistAlz, Lille, France,Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 days for health, EGID, Lille, France
| | - Manuel Tena-Sempere
- Univ. Cordoba, IMIBC/HURS, CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Cordoba, Spain
| | - Marc Claret
- Neuronal Control of Metabolism Laboratory, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red (CIBER) de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 08036 Barcelona, Spain
| | - Ariane Paoloni-Giacobino
- Department of Genetic Medicine, University Hospitals of Geneva, 4 rue Gabrielle-Perret-Gentil, 1211, Genève 14, Switzerland
| | - Damien Plassard
- CNRS UMR 7104, INSERM U1258, GenomEast Platform, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg, Illkirch, France
| | - Emmanuelle Paccou
- Department of Endocrinology, Diabetology, and Metabolism, Lausanne University Hospital, 1011 Lausanne, Switzerland
| | - Nathalie Vionnet
- Department of Endocrinology, Diabetology, and Metabolism, Lausanne University Hospital, 1011 Lausanne, Switzerland
| | - James Acierno
- Department of Endocrinology, Diabetology, and Metabolism, Lausanne University Hospital, 1011 Lausanne, Switzerland
| | - Aleksandra Maleska Maceski
- Neurologic Clinic and Polyclinic, MS Centre and Research Centre for Clinical Neuroimmunology and Neuroscience Basel; University Hospital Basel, University of Basel, Basel Switzerland
| | - Antoine Lutti
- Laboratory for Research in Neuroimaging LREN, Centre for Research in Neurosciences, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Switzerland
| | - Frank Pfrieger
- Centre National de la Recherche Scientifique, Université de Strasbourg, Institut des Neurosciences Cellulaires et Intégratives, 67000 Strasbourg, France
| | - S. Rasika
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S 1172, LabexDistAlz, Lille, France,Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 days for health, EGID, Lille, France
| | - Federico Santoni
- Faculty of Biology and Medicine, University of Lausanne, Lausanne 1005, Switzerland
| | - Ulrich Boehm
- Experimental Pharmacology, Center for Molecular Signaling (PZMS), Saarland University School of Medicine, 66421, Homburg, Germany
| | - Philippe Ciofi
- Univ. Bordeaux, Inserm, U1215, Neurocentre Magendie, Bordeaux, France
| | - Luc Buée
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S 1172, LabexDistAlz, Lille, France
| | - Nasser Haddjeri
- Univ. Lyon, Université Claude Bernard Lyon 1, Inserm, Stem Cell and Brain Research Institute U1208, Bron 69500, France
| | - Anne-Laurence Boutillier
- Laboratoire de Neurosciences Cognitives et Adaptatives (LNCA), UMR 7364, Université de Strasbourg-CNRS, Strasbourg, France
| | - Jens Kuhle
- Neurologic Clinic and Polyclinic, MS Centre and Research Centre for Clinical Neuroimmunology and Neuroscience Basel; University Hospital Basel, University of Basel, Basel Switzerland
| | - Andrea Messina
- Department of Endocrinology, Diabetology, and Metabolism, Lausanne University Hospital, 1011 Lausanne, Switzerland,Faculty of Biology and Medicine, University of Lausanne, Lausanne 1005, Switzerland
| | - Bogdan Draganski
- Laboratory for Research in Neuroimaging LREN, Centre for Research in Neurosciences, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Switzerland,Neurology Department, Max-Planck-Institute for Human Cognitive and Brain Sciences, Leipzig, Germany
| | - Paolo Giacobini
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S 1172, LabexDistAlz, Lille, France,Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 days for health, EGID, Lille, France
| | - Nelly Pitteloud
- Department of Endocrinology, Diabetology, and Metabolism, Lausanne University Hospital, 1011 Lausanne, Switzerland,Faculty of Biology and Medicine, University of Lausanne, Lausanne 1005, Switzerland,Correspondence to: and (+33 612903876)
| | - Vincent Prevot
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S 1172, LabexDistAlz, Lille, France,Laboratory of Development and Plasticity of the Neuroendocrine Brain, FHU 1000 days for health, EGID, Lille, France,Correspondence to: and (+33 612903876)
| |
Collapse
|
2
|
Lam S, Hérard AS, Boluda S, Petit F, Eddarkaoui S, Cambon K, Picq JL, Buée L, Duyckaerts C, Haïk S, Dhenain M. Pathological changes induced by Alzheimer's brain inoculation in amyloid-beta plaque-bearing mice. Acta Neuropathol Commun 2022; 10:112. [PMID: 35974399 PMCID: PMC9380345 DOI: 10.1186/s40478-022-01410-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2022] [Accepted: 07/16/2022] [Indexed: 12/24/2022] Open
Abstract
Alzheimer's disease (AD) is characterized by intracerebral accumulations of extracellular amyloid-β (Aβ) plaques and intracellular tau pathology that spread in the brain. Three types of tau lesions occur in the form of neuropil threads, neurofibrillary tangles, and neuritic plaques i.e. tau aggregates within neurites surrounding Aβ deposits. The cascade of events linking these lesions and synaptic or memory impairments are still debated. Intracerebral infusion of human AD brain extracts in Aβ plaque-bearing mice that do not overexpress pathological tau proteins induces tau pathologies following heterotopic seeding of mouse tau protein. There is however little information regarding the downstream events including synaptic or cognitive repercussions of tau pathology induction in these models. In the present study, human AD brain extracts (ADbe) and control-brain extracts (Ctrlbe) were infused into the hippocampus of Aβ plaque-bearing APPswe/PS1dE9 mice. Memory, synaptic density, as well as Aβ plaque and tau aggregate loads, microgliosis, astrogliosis at the inoculation site and in connected regions (perirhinal/entorhinal cortex) were evaluated 4 and 8 months post-inoculation. ADbe inoculation produced the following effects: (i) memory deficit; (ii) increased Aβ plaque deposition in proximity to the inoculation site; (iii) tau pathology induction; (iv) appearance of neuropil threads and neurofibrillary tangles next to the inoculation site with a spreading to connected regions. Neuritic plaque pathology was detected in both ADbe- and Ctrlbe-inoculated animals but ADbe inoculation increased the severity close to and at distance of the inoculation site. (v) Finally, ADbe inoculation reduced synaptic density in the vicinity to the inoculation site and in connected regions as the perirhinal/entorhinal cortex. Synaptic impairments were correlated with increased severity of neuritic plaques but not to other tau lesions or Aβ lesions, suggesting that neuritic plaques are a culprit for synaptic loss. Synaptic density was also associated with microglial load.
Collapse
Affiliation(s)
- Suzanne Lam
- CEA, CNRS, Laboratoire des Maladies Neurodégénératives, MIRCen, Université Paris-Saclay, 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.,Direction de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), 18 Route du Panorama, 92265, Fontenay-aux-Roses, France
| | - Anne-Sophie Hérard
- CEA, CNRS, Laboratoire des Maladies Neurodégénératives, MIRCen, Université Paris-Saclay, 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.,Direction de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), 18 Route du Panorama, 92265, Fontenay-aux-Roses, France
| | - Susana Boluda
- ICM Institut du Cerveau et de la Moelle épinière, CNRS UMR7225, INSERM U1127, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France.,Brainbank NeuroCEB Neuropathology Network: Plate-Forme de Ressources Biologiques, Bâtiment Roger Baillet, Hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75651, Paris Cedex 13, France
| | - Fanny Petit
- CEA, CNRS, Laboratoire des Maladies Neurodégénératives, MIRCen, Université Paris-Saclay, 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.,Direction de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), 18 Route du Panorama, 92265, Fontenay-aux-Roses, France
| | - Sabiha Eddarkaoui
- Inserm, CHU-Lille, Lille Neuroscience & Cognition, Alzheimer & Tauopathies, LabEx DISTALZ, Université de Lille, Rue Polonovski, 59045, Lille, France
| | - Karine Cambon
- CEA, CNRS, Laboratoire des Maladies Neurodégénératives, MIRCen, Université Paris-Saclay, 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.,Direction de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), 18 Route du Panorama, 92265, Fontenay-aux-Roses, France
| | | | - Jean-Luc Picq
- CEA, CNRS, Laboratoire des Maladies Neurodégénératives, MIRCen, Université Paris-Saclay, 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.,Direction de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.,Laboratory of Cognitive Functioning and Dysfunctioning (DysCo), University Paris 8, 93526, Saint-Denis Cedex, France
| | - Luc Buée
- Inserm, CHU-Lille, Lille Neuroscience & Cognition, Alzheimer & Tauopathies, LabEx DISTALZ, Université de Lille, Rue Polonovski, 59045, Lille, France
| | - Charles Duyckaerts
- ICM Institut du Cerveau et de la Moelle épinière, CNRS UMR7225, INSERM U1127, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France.,Brainbank NeuroCEB Neuropathology Network: Plate-Forme de Ressources Biologiques, Bâtiment Roger Baillet, Hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75651, Paris Cedex 13, France
| | - Stéphane Haïk
- ICM Institut du Cerveau et de la Moelle épinière, CNRS UMR7225, INSERM U1127, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France.,Brainbank NeuroCEB Neuropathology Network: Plate-Forme de Ressources Biologiques, Bâtiment Roger Baillet, Hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75651, Paris Cedex 13, France
| | - Marc Dhenain
- CEA, CNRS, Laboratoire des Maladies Neurodégénératives, MIRCen, Université Paris-Saclay, 18 Route du Panorama, 92265, Fontenay-aux-Roses, France. .,Direction de la Recherche Fondamentale (DRF), Institut François Jacob, MIRCen, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), 18 Route du Panorama, 92265, Fontenay-aux-Roses, France.
| |
Collapse
|
3
|
Coku I, Mutez E, Eddarkaoui S, Carrier S, Marchand A, Deldycke C, Goveas L, Baille G, Tir M, Magnez R, Thuru X, Vermeersch G, Vandenberghe W, Buée L, Defebvre L, Sablonnière B, Chartier-Harlin MC, Taymans JM, Huin V. Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson's Disease. Mov Disord 2022; 37:1761-1767. [PMID: 35708213 PMCID: PMC9543145 DOI: 10.1002/mds.29124] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Revised: 04/20/2022] [Accepted: 05/13/2022] [Indexed: 11/29/2022] Open
Abstract
Background Pathogenic variants in the LRRK2 gene are a common monogenic cause of Parkinson's disease. However, only seven variants have been confirmed to be pathogenic. Objectives We identified two novel LRRK2 variants (H230R and A1440P) and performed functional testing. Methods We transiently expressed wild‐type, the two new variants, or two known pathogenic mutants (G2019S and R1441G) in HEK‐293 T cells, with or without LRRK2 kinase inhibitor treatment. We characterized the phosphorylation and kinase activity of the mutants by western blotting. Thermal shift assays were performed to determine the folding and stability of the LRRK2 proteins. Results The two variants were found in two large families and segregate with the disease. They display altered LRRK2 phosphorylation and kinase activity. Conclusions We identified two novel LRRK2 variants which segregate with the disease. The results of functional testing lead us to propose these two variants as novel causative mutations for familial Parkinson's disease. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Collapse
Affiliation(s)
- Ilda Coku
- University of Lille, Inserm, CHU Lille, U1172-LilNCog (JPARC)-Lille Neuroscience & Cognition, Lille, France
| | - Eugénie Mutez
- University of Lille, Inserm, CHU Lille, U1172-LilNCog (JPARC)-Lille Neuroscience & Cognition, Lille, France.,University of Lille, Inserm, CHU Lille, Expert Center for Parkinson's Disease, Lille, France
| | - Sabiha Eddarkaoui
- University of Lille, Inserm, CHU Lille, U1172-LilNCog (JPARC)-Lille Neuroscience & Cognition, Lille, France
| | - Sébastien Carrier
- University of Lille, Inserm, CHU Lille, U1172-LilNCog (JPARC)-Lille Neuroscience & Cognition, Lille, France
| | - Antoine Marchand
- University of Lille, Inserm, CHU Lille, U1172-LilNCog (JPARC)-Lille Neuroscience & Cognition, Lille, France
| | - Claire Deldycke
- University of Lille, Inserm, CHU Lille, U1172-LilNCog (JPARC)-Lille Neuroscience & Cognition, Lille, France
| | - Liesel Goveas
- University of Lille, Inserm, CHU Lille, U1172-LilNCog (JPARC)-Lille Neuroscience & Cognition, Lille, France
| | - Guillaume Baille
- University of Lille, Inserm, CHU Lille, Expert Center for Parkinson's Disease, Lille, France
| | - Mélissa Tir
- Department of Neurology and Expert Center for Parkinson's Disease, Amiens University Hospital, CHU Amiens-Picardie, Amiens, France
| | - Romain Magnez
- University of Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
| | - Xavier Thuru
- University of Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
| | | | - Wim Vandenberghe
- Department of Neurology, University Hospitals Leuven, Leuven, Belgium.,Laboratory for Parkinson Research, Department of Neurosciences, KU Leuven, Leuven, Belgium
| | - Luc Buée
- University of Lille, Inserm, CHU Lille, U1172-LilNCog (JPARC)-Lille Neuroscience & Cognition, Lille, France
| | - Luc Defebvre
- University of Lille, Inserm, CHU Lille, U1172-LilNCog (JPARC)-Lille Neuroscience & Cognition, Lille, France.,University of Lille, Inserm, CHU Lille, Expert Center for Parkinson's Disease, Lille, France
| | - Bernard Sablonnière
- University of Lille, Inserm, CHU Lille, U1172-LilNCog (JPARC)-Lille Neuroscience & Cognition, Lille, France.,University of Lille, Inserm, CHU Lille, Department of Toxicology and Genopathies, UF Neurobiology, Lille, France
| | | | - Jean-Marc Taymans
- University of Lille, Inserm, CHU Lille, U1172-LilNCog (JPARC)-Lille Neuroscience & Cognition, Lille, France
| | - Vincent Huin
- University of Lille, Inserm, CHU Lille, U1172-LilNCog (JPARC)-Lille Neuroscience & Cognition, Lille, France.,University of Lille, Inserm, CHU Lille, Department of Toxicology and Genopathies, UF Neurobiology, Lille, France
| |
Collapse
|
4
|
Paiva I, Cellai L, Meriaux C, Poncelet L, Nebie O, Saliou JM, Lacoste AS, Papegaey A, Drobecq H, Le Gras S, Schneider M, Malik EM, Müller CE, Faivre E, Carvalho K, Gomez-Murcia V, Vieau D, Thiroux B, Eddarkaoui S, Lebouvier T, Schueller E, Tzeplaeff L, Grgurina I, Seguin J, Stauber J, Lopes LV, Buee L, Buée-Scherrer V, Cunha RA, Ait-Belkacem R, Sergeant N, Annicotte JS, Boutillier AL, Blum D. Caffeine intake exerts dual genome-wide effects on hippocampal metabolism and learning-dependent transcription. J Clin Invest 2022; 132:149371. [PMID: 35536645 PMCID: PMC9197525 DOI: 10.1172/jci149371] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Accepted: 05/05/2022] [Indexed: 12/01/2022] Open
Abstract
Caffeine is the most widely consumed psychoactive substance in the world. Strikingly, the molecular pathways engaged by its regular consumption remain unclear. We herein addressed the mechanisms associated with habitual (chronic) caffeine consumption in the mouse hippocampus using untargeted orthogonal omics techniques. Our results revealed that chronic caffeine exerts concerted pleiotropic effects in the hippocampus at the epigenomic, proteomic, and metabolomic levels. Caffeine lowered metabolism-related processes (e.g., at the level of metabolomics and gene expression) in bulk tissue, while it induced neuron-specific epigenetic changes at synaptic transmission/plasticity-related genes and increased experience-driven transcriptional activity. Altogether, these findings suggest that regular caffeine intake improves the signal-to-noise ratio during information encoding, in part through fine-tuning of metabolic genes, while boosting the salience of information processing during learning in neuronal circuits.
Collapse
Affiliation(s)
- Isabel Paiva
- Laboratoire de Neuroscience Cognitives et Adaptatives, University of Strasbourg, CNRS, UMR7364, Strasbourg, France
| | | | - Céline Meriaux
- Alzheimer and Tauopathies, Inserm UMR-S1172, Lille, France
| | | | - Ouada Nebie
- Alzheimer and Tauopathies, Inserm UMR-S1172, Lille, France
| | | | | | | | - Hervé Drobecq
- CIIL - Centre d'Infection et d'Immunité de Lille (CIIL), Inserm 1019, Lille, France
| | - Stéphanie Le Gras
- GenomEast Platform, University Strasbourg, CNRS UMR 7104, Inserm U1258, Lille, France
| | - Marion Schneider
- PharmaCenter Bonn, Pharmaceutical Institute, University of Bonn, Bonn, Germany
| | - Enas M Malik
- PharmaCenter Bonn, Pharmaceutical Institute, University of Bonn, Bonn, Germany
| | - Christa E Müller
- PharmaCenter Bonn, Pharmaceutical Institute, University of Bonn, Bonn, Germany
| | - Emilie Faivre
- Alzheimer and Tauopathies, Inserm UMR-S1172, Lille, France
| | - Kevin Carvalho
- Alzheimer and Tauopathies, Inserm UMR-S1172, Lille, France
| | | | - Didier Vieau
- Alzheimer and Tauopathies, Inserm UMR-S1172, Lille, France
| | - Bryan Thiroux
- Alzheimer and Tauopathies, Inserm UMR-S1172, Lille, France
| | | | | | - Estelle Schueller
- Laboratoire de Neuroscience Cognitives et Adaptatives, Université de Strasbourg, Strasbourg, France
| | - Laura Tzeplaeff
- Laboratoire de Neuroscience Cognitives et Adaptatives, University of Strasbourg, Strasbourg, France
| | - Iris Grgurina
- Laboratoire de Neuroscience Cognitives et Adaptatives, Université de Strasbourg, Strasbourg, France
| | - Jonathan Seguin
- Laboratoire de Neuroscience Cognitives et Adaptatives, Université de Strasbourg, Strasbourg, France
| | | | - Luisa V Lopes
- Instituto de Medicina Molecular, Universidade de Lisboa, Lisboa, Portugal
| | - Luc Buee
- Alzheimer and Tauopathies, Inserm UMR-S1172, Lille, France
| | | | - Rodrigo A Cunha
- Center for Neuroscience of Coimbra, University of Coimbra, Coimbra, Portugal
| | | | | | | | - Anne-Laurence Boutillier
- Laboratoire de Neuroscience Cognitives et Adaptatives, Université de Strasbourg, Strasbourg, France
| | - David Blum
- INSERM U837, University Lille-Nord de France, UDSL, Lille, France
| |
Collapse
|
5
|
Benderradji H, Kraiem S, Courty E, Eddarkaoui S, Bourouh C, Faivre E, Rolland L, Caron E, Besegher M, Oger F, Boschetti T, Carvalho K, Thiroux B, Gauvrit T, Nicolas E, Gomez-Murcia V, Bogdanova A, Bongiovanni A, Muhr-Tailleux A, Lancel S, Bantubungi K, Sergeant N, Annicotte JS, Buée L, Vieau D, Blum D, Buée-Scherrer V. Impaired Glucose Homeostasis in a Tau Knock-In Mouse Model. Front Mol Neurosci 2022; 15:841892. [PMID: 35250480 PMCID: PMC8889017 DOI: 10.3389/fnmol.2022.841892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 01/21/2022] [Indexed: 11/13/2022] Open
Abstract
Alzheimer’s disease (AD) is the leading cause of dementia. While impaired glucose homeostasis has been shown to increase AD risk and pathological loss of tau function, the latter has been suggested to contribute to the emergence of the glucose homeostasis alterations observed in AD patients. However, the links between tau impairments and glucose homeostasis, remain unclear. In this context, the present study aimed at investigating the metabolic phenotype of a new tau knock-in (KI) mouse model, expressing, at a physiological level, a human tau protein bearing the P301L mutation under the control of the endogenous mouse Mapt promoter. Metabolic investigations revealed that, while under chow diet tau KI mice do not exhibit significant metabolic impairments, male but not female tau KI animals under High-Fat Diet (HFD) exhibited higher insulinemia as well as glucose intolerance as compared to control littermates. Using immunofluorescence, tau protein was found colocalized with insulin in the β cells of pancreatic islets in both mouse (WT, KI) and human pancreas. Isolated islets from tau KI and tau knock-out mice exhibited impaired glucose-stimulated insulin secretion (GSIS), an effect recapitulated in the mouse pancreatic β-cell line (MIN6) following tau knock-down. Altogether, our data indicate that loss of tau function in tau KI mice and, particularly, dysfunction of pancreatic β cells might promote glucose homeostasis impairments and contribute to metabolic changes observed in AD.
Collapse
Affiliation(s)
- Hamza Benderradji
- Univ. Lille, Inserm, CHU Lille, U1172 LilNCog—Lille Neuroscience & Cognition, Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, Lille, France
| | - Sarra Kraiem
- Univ. Lille, Inserm, CHU Lille, U1172 LilNCog—Lille Neuroscience & Cognition, Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, Lille, France
| | - Emilie Courty
- Univ. Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, Inserm U1283-UMR8199—EGID, Lille, France
| | - Sabiha Eddarkaoui
- Univ. Lille, Inserm, CHU Lille, U1172 LilNCog—Lille Neuroscience & Cognition, Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, Lille, France
| | - Cyril Bourouh
- Univ. Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, Inserm U1283-UMR8199—EGID, Lille, France
| | - Emilie Faivre
- Univ. Lille, Inserm, CHU Lille, U1172 LilNCog—Lille Neuroscience & Cognition, Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, Lille, France
| | - Laure Rolland
- Univ. Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, Inserm U1283-UMR8199—EGID, Lille, France
| | - Emilie Caron
- Univ. Lille, Inserm, CHU Lille, U1172 LilNCog—Lille Neuroscience & Cognition, Lille, France
- Development and Plasticity of the Neuroendocrine Brain, Lille, France
| | - Mélanie Besegher
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41—UMS 2014—PLBS, Animal Facility, Lille, France
| | - Frederik Oger
- Univ. Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, Inserm U1283-UMR8199—EGID, Lille, France
| | - Theo Boschetti
- Univ. Lille, Inserm, CHU Lille, U1172 LilNCog—Lille Neuroscience & Cognition, Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, Lille, France
| | - Kévin Carvalho
- Univ. Lille, Inserm, CHU Lille, U1172 LilNCog—Lille Neuroscience & Cognition, Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, Lille, France
| | - Bryan Thiroux
- Univ. Lille, Inserm, CHU Lille, U1172 LilNCog—Lille Neuroscience & Cognition, Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, Lille, France
| | - Thibaut Gauvrit
- Univ. Lille, Inserm, CHU Lille, U1172 LilNCog—Lille Neuroscience & Cognition, Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, Lille, France
| | - Emilie Nicolas
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France
| | - Victoria Gomez-Murcia
- Univ. Lille, Inserm, CHU Lille, U1172 LilNCog—Lille Neuroscience & Cognition, Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, Lille, France
| | - Anna Bogdanova
- Univ. Lille, Inserm, CHU Lille, U1172 LilNCog—Lille Neuroscience & Cognition, Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, Lille, France
| | - Antonino Bongiovanni
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41—UMS 2014—PLBS, BioImaging Center Lille, Lille, France
| | - Anne Muhr-Tailleux
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France
| | - Steve Lancel
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167—RID-AGE—Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France
| | - Kadiombo Bantubungi
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France
| | - Nicolas Sergeant
- Univ. Lille, Inserm, CHU Lille, U1172 LilNCog—Lille Neuroscience & Cognition, Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, Lille, France
| | - Jean-Sebastien Annicotte
- Univ. Lille, INSERM, CNRS, CHU Lille, Institut Pasteur de Lille, Inserm U1283-UMR8199—EGID, Lille, France
| | - Luc Buée
- Univ. Lille, Inserm, CHU Lille, U1172 LilNCog—Lille Neuroscience & Cognition, Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, Lille, France
| | - Didier Vieau
- Univ. Lille, Inserm, CHU Lille, U1172 LilNCog—Lille Neuroscience & Cognition, Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, Lille, France
| | - David Blum
- Univ. Lille, Inserm, CHU Lille, U1172 LilNCog—Lille Neuroscience & Cognition, Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, Lille, France
- *Correspondence: David Blum
| | - Valérie Buée-Scherrer
- Univ. Lille, Inserm, CHU Lille, U1172 LilNCog—Lille Neuroscience & Cognition, Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, Lille, France
| |
Collapse
|
6
|
Danis C, Dupré E, Zejneli O, Caillierez R, Arrial A, Bégard S, Mortelecque J, Eddarkaoui S, Loyens A, Cantrelle FX, Hanoulle X, Rain JC, Colin M, Buée L, Landrieu I. Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment. Mol Ther 2022; 30:1484-1499. [PMID: 35007758 PMCID: PMC9077319 DOI: 10.1016/j.ymthe.2022.01.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Revised: 12/07/2021] [Accepted: 01/05/2022] [Indexed: 01/13/2023] Open
Abstract
Tau proteins aggregate into filaments in brain cells in Alzheimer's disease and related disorders referred to as tauopathies. Here, we used fragments of camelid heavy-chain-only antibodies (VHHs or single domain antibody fragments) targeting Tau as immuno-modulators of its pathologic seeding. A VHH issued from the screen against Tau of a synthetic phage-display library of humanized VHHs was selected for its capacity to bind Tau microtubule-binding domain, composing the core of Tau fibrils. This parent VHH was optimized to improve its biochemical properties and to act in the intra-cellular compartment, resulting in VHH Z70. VHH Z70 precisely binds the PHF6 sequence, known for its nucleation capacity, as shown by the crystal structure of the complex. VHH Z70 was more efficient than the parent VHH to inhibit in vitro Tau aggregation in heparin-induced assays. Expression of VHH Z70 in a cellular model of Tau seeding also decreased the aggregation-reporting fluorescence signal. Finally, intra-cellular expression of VHH Z70 in the brain of an established tauopathy mouse seeding model demonstrated its capacity to mitigate accumulation of pathological Tau. VHH Z70, by targeting Tau inside brain neurons, where most of the pathological Tau resides, provides an immunological tool to target the intra-cellular compartment in tauopathies.
Collapse
Affiliation(s)
- Clément Danis
- CNRS, EMR9002 BSI Integrative Structural Biology, 59000 Lille, France; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Risk Factors and Molecular Determinants of Aging-Related Diseases, 59000 Lille, France; Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France
| | - Elian Dupré
- CNRS, EMR9002 BSI Integrative Structural Biology, 59000 Lille, France; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Risk Factors and Molecular Determinants of Aging-Related Diseases, 59000 Lille, France; Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France
| | - Orgeta Zejneli
- CNRS, EMR9002 BSI Integrative Structural Biology, 59000 Lille, France; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Risk Factors and Molecular Determinants of Aging-Related Diseases, 59000 Lille, France; Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France
| | - Raphaëlle Caillierez
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France
| | - Alexis Arrial
- Hybrigenic Services, Evry-Courcouronnes 91000, France
| | - Séverine Bégard
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France
| | - Justine Mortelecque
- CNRS, EMR9002 BSI Integrative Structural Biology, 59000 Lille, France; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Risk Factors and Molecular Determinants of Aging-Related Diseases, 59000 Lille, France
| | - Sabiha Eddarkaoui
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France
| | - Anne Loyens
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France
| | - François-Xavier Cantrelle
- CNRS, EMR9002 BSI Integrative Structural Biology, 59000 Lille, France; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Risk Factors and Molecular Determinants of Aging-Related Diseases, 59000 Lille, France
| | - Xavier Hanoulle
- CNRS, EMR9002 BSI Integrative Structural Biology, 59000 Lille, France; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Risk Factors and Molecular Determinants of Aging-Related Diseases, 59000 Lille, France
| | | | - Morvane Colin
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France
| | - Luc Buée
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France.
| | - Isabelle Landrieu
- CNRS, EMR9002 BSI Integrative Structural Biology, 59000 Lille, France; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Risk Factors and Molecular Determinants of Aging-Related Diseases, 59000 Lille, France.
| |
Collapse
|
7
|
Lam S, Petit F, Hérard AS, Boluda S, Eddarkaoui S, Guillermier M, Letournel F, Martin-Négrier ML, Faisant M, Godfraind C, Boutonnat J, Maurage CA, Deramecourt V, Duchesne M, Meyronet D, Fenouil T, de Paula AM, Rigau V, Vandenbos-Burel F, Seilhean D, Duyckaerts C, Boluda S, Plu I, Chiforeanu DC, Laquerrière A, Marguet F, Lannes B, Lhermitte B, Buée L, Duyckaerts C, Haïk S, Picq JL, Dhenain M. Transmission of amyloid-beta and tau pathologies is associated with cognitive impairments in a primate. Acta Neuropathol Commun 2021; 9:165. [PMID: 34641980 PMCID: PMC8507137 DOI: 10.1186/s40478-021-01266-8] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Accepted: 09/22/2021] [Indexed: 11/10/2022] Open
Abstract
Amyloid-β (Aβ) pathology transmission has been described in patients following iatrogenic exposure to compounds contaminated with Aβ proteins. It can induce cerebral Aβ angiopathy resulting in brain hemorrhages and devastating clinical impacts. Iatrogenic transmission of tau pathology is also suspected but not experimentally proven. In both scenarios, lesions were detected several decades after the putatively triggering medico-surgical act. There is however little information regarding the cognitive repercussions in individuals who do not develop cerebral hemorrhages. In the current study, we inoculated the posterior cingulate cortex and underlying corpus callosum of young adult primates (Microcebus murinus) with either Alzheimer's disease or control brain extracts. This led to widespread Aβ and tau pathologies in all of the Alzheimer-inoculated animals following a 21-month-long incubation period (n = 12) whereas none of the control brain extract-inoculated animals developed such lesions (n = 6). Aβ deposition affected almost all cortical regions. Tau pathology was also detected in Aβ-deposit-free regions distant from the inoculation sites (e.g. in the entorhinal cortex), while some regions adjacent, but not connected, to the inoculation sites were spared (e.g. the occipital cortex). Alzheimer-inoculated animals developed cognitive deficits and cerebral atrophy compared to controls. These pathologies were induced using two different batches of Alzheimer brain extracts. This is the first experimental demonstration that tau can be transmitted by human brain extracts inoculations in a primate. We also showed for the first time that the transmission of widespread Aβ and tau pathologies can be associated with cognitive decline. Our results thus reinforce the need to organize a systematic monitoring of individuals who underwent procedures associated with a risk of Aβ and tau iatrogenic transmission. They also provide support for Alzheimer brain-inoculated primates as relevant models of Alzheimer pathology.
Collapse
|
8
|
Tautou M, Eddarkaoui S, Descamps F, Larchanché PE, El Bakali J, Goveas LM, Dumoulin M, Lamarre C, Blum D, Buée L, Melnyk P, Sergeant N. A ß-Secretase Modulator Decreases Tau Pathology and Preserves Short-Term Memory in a Mouse Model of Neurofibrillary Degeneration. Front Pharmacol 2021; 12:679335. [PMID: 34267657 PMCID: PMC8276176 DOI: 10.3389/fphar.2021.679335] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Accepted: 05/18/2021] [Indexed: 01/24/2023] Open
Abstract
Identifying which among several in cellulo pharmacological activities is necessary for the proper in vivo activity is essential for further drug development against Alzheimer’s disease pathophysiological processes. An in-depth structure–activity relationship–based study has been carried out, and two molecules, named MAGS02-14 and PEL24-199, that share a ß-secretase modulatory effect associated or not to a lysosomotropic activity in cellulo have been identified. In terms of chemical formulas, MAGS02-14 and PEL24-199 only differ from each other by a single nitrogen atom. The study aimed to elucidate the in vivo pharmacological effects of lysosomotropic and/or the ß-secretase modulatory activity in a tau pathology mouse model. To address this question, the THY-Tau22 transgenic model of tauopathy was treated with both compounds for 6 weeks in a curative paradigm. Short-term memory, tau burden, and inflammatory processes were analyzed using orthogonal methods, and PEL24-199, but not MAGS02-14, was shown to restore the short-term memory and reduce the neurofibrillary degenerating process. These effects were associated with a reduced phosphorylation of tau, an increased phosphatase expression, and decreased astrogliosis. Our results, therefore, suggest that the lysosomotropic activity may be nonessential for the effect on tau pathology.
Collapse
Affiliation(s)
- Marie Tautou
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France
| | - Sabiha Eddarkaoui
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France.,Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France
| | - Florian Descamps
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France
| | - Paul-Emmanuel Larchanché
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France
| | - Jamal El Bakali
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France
| | - Liesel Mary Goveas
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France
| | - Mélanie Dumoulin
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France
| | - Chloé Lamarre
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France
| | - David Blum
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France.,Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France
| | - Luc Buée
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France.,Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France
| | - Patricia Melnyk
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France
| | - Nicolas Sergeant
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France.,Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France
| |
Collapse
|
9
|
Homa M, Loyens A, Eddarkaoui S, Faivre E, Deramecourt V, Maurage CA, Buée L, Huin V, Sablonnière B. The TMEM240 Protein, Mutated in SCA21, Is Expressed in Purkinje Cells and Synaptic Terminals. Cerebellum 2021; 19:358-369. [PMID: 32002801 DOI: 10.1007/s12311-020-01112-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
A variety of missense mutations and a stop mutation in the gene coding for transmembrane protein 240 (TMEM240) have been reported to be the causative mutations of spinocerebellar ataxia 21 (SCA21). We aimed to investigate the expression of TMEM240 protein in mouse brain at the tissue, cellular, and subcellular levels. Immunofluorescence labeling showed TMEM240 to be expressed in various areas of the brain, with the highest levels in the hippocampus, isocortex, and cerebellum. In the cerebellum, TMEM240 was detected in the deep nuclei and the cerebellar cortex. The protein was expressed in all three layers of the cortex and various cerebellar neurons. TMEM240 was localized to climbing, mossy, and parallel fiber afferents projecting to Purkinje cells, as shown by co-immunostaining with VGLUT1 and VGLUT2. Co-immunostaining with synaptophysin, post-synaptic fractionation, and confirmatory electron microscopy showed TMEM240 to be localized to the post-synaptic side of synapses near the Purkinje-cell soma. Similar results were obtained in human cerebellar sections. These data suggest that TMEM240 may be involved in the organization of the cerebellar network, particularly in synaptic inputs converging on Purkinje cells. This study is the first to describe TMEM240 expression in the normal mouse brain.
Collapse
Affiliation(s)
- Mégane Homa
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000, Lille, France
| | - Anne Loyens
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000, Lille, France
| | - Sabiha Eddarkaoui
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000, Lille, France
| | - Emilie Faivre
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000, Lille, France
| | - Vincent Deramecourt
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000, Lille, France
| | - Claude-Alain Maurage
- CHU Lille, Laboratoire d'Anatomopathologie, Centre de Biologie Pathologie et Génétique, F-59000, Lille, France
| | - Luc Buée
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000, Lille, France
| | - Vincent Huin
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000, Lille, France. .,CHU Lille, Institut de Biochimie et Biologie moléculaire, Centre de Biologie Pathologie et Génétique, F-59000, Lille, France.
| | - Bernard Sablonnière
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000, Lille, France.,CHU Lille, Institut de Biochimie et Biologie moléculaire, Centre de Biologie Pathologie et Génétique, F-59000, Lille, France
| |
Collapse
|
10
|
Dhenain M, Lam S, Gary C, Herard A, Koch J, Petit F, Gipchtein P, Sawiak S, Caillierez R, Eddarkaoui S, Colin M, Aujard F, Deslys J, Duyckaerts C, Brouillet E, Comoy E, Pifferi F, Picq J. Iatrogenic transmission of Alzheimer's disease: Evidence based on experimental inoculation of Alzheimer's brains into a primate. Alzheimers Dement 2020. [DOI: 10.1002/alz.042957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Marc Dhenain
- Centre National de la Recherche Scientifique (CNRS) Fontenay‐aux‐Roses France
| | | | - Charlotte Gary
- Commissariat a l Energie Atomique et aux Energies Alternatives (CEA) Fontenay‐aux‐Roses France
| | - Anne‐Sophie Herard
- Commissariat a l Energie Atomique et aux Energies Alternatives (CEA) Fontenay‐aux‐Roses France
| | - James Koch
- University of Wisconsin Oshkosh WI France
| | - Fanny Petit
- Commissariat a l Energie Atomique et aux Energies Alternatives (CEA) Fontenay‐aux‐Roses France
| | | | - Stephen Sawiak
- Behavioural and Clinical Neuroscience Institute University of Cambridge Cambridge United Kingdom
| | | | | | | | - Fabienne Aujard
- Centre National de la Recherche Scientifique of Brunoy Brunoy France
| | - Jean‐Philippe Deslys
- Commissariat a l Energie Atomique et aux Energies Alternatives (CEA) Fontenay‐aux‐Roses France
| | - Charles Duyckaerts
- Neuropathology Laboratory Raymond Escourolle Assistance Publique des Hôpitaux de Paris Paris France
| | - Emmanuel Brouillet
- Centre National de la Recherche Scientifique (CNRS) Fontenay‐aux‐Roses France
| | - Emmanuel Comoy
- Commissariat a l Energie Atomique et aux Energies Alternatives (CEA) Fontenay‐aux‐Roses France
| | - Fabien Pifferi
- Centre National de la Recherche Scientifique (CNRS) Brunoy France
| | - Jean‐Luc Picq
- Centre National de la Recherche Scientifique (CNRS) Fontenay‐aux‐Roses France
| | | |
Collapse
|
11
|
Richetin K, Steullet P, Pachoud M, Perbet R, Parietti E, Maheswaran M, Eddarkaoui S, Bégard S, Pythoud C, Rey M, Caillierez R, Q Do K, Halliez S, Bezzi P, Buée L, Leuba G, Colin M, Toni N, Déglon N. Tau accumulation in astrocytes of the dentate gyrus induces neuronal dysfunction and memory deficits in Alzheimer's disease. Nat Neurosci 2020; 23:1567-1579. [PMID: 33169029 DOI: 10.1038/s41593-020-00728-x] [Citation(s) in RCA: 90] [Impact Index Per Article: 22.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2018] [Accepted: 09/24/2020] [Indexed: 12/20/2022]
Abstract
Alzheimer's disease (AD) is characterized by the accumulation of the tau protein in neurons, neurodegeneration and memory loss. However, the role of non-neuronal cells in this chain of events remains unclear. In the present study, we found accumulation of tau in hilar astrocytes of the dentate gyrus of individuals with AD. In mice, the overexpression of 3R tau specifically in hilar astrocytes of the dentate gyrus altered mitochondrial dynamics and function. In turn, these changes led to a reduction of adult neurogenesis, parvalbumin-expressing neurons, inhibitory synapses and hilar gamma oscillations, which were accompanied by impaired spatial memory performances. Together, these results indicate that the loss of tau homeostasis in hilar astrocytes of the dentate gyrus is sufficient to induce AD-like symptoms, through the impairment of the neuronal network. These results are important for our understanding of disease mechanisms and underline the crucial role of astrocytes in hippocampal function.
Collapse
Affiliation(s)
- Kevin Richetin
- Department of Psychiatry, Center for Psychiatric Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland. .,Laboratory of Neurotherapies and Neuromodulation, Neuroscience Research Center (CRN), Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland. .,Department of Clinical Neuroscience (DNC), Laboratory of Neurotherapies and Neuromodulation, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
| | - Pascal Steullet
- Department of Psychiatry, Center for Psychiatric Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Mathieu Pachoud
- Laboratory of Neurotherapies and Neuromodulation, Neuroscience Research Center (CRN), Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.,Department of Clinical Neuroscience (DNC), Laboratory of Neurotherapies and Neuromodulation, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Romain Perbet
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille, France
| | - Enea Parietti
- Department of Psychiatry, Center for Psychiatric Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Mathischan Maheswaran
- Laboratory of Neurotherapies and Neuromodulation, Neuroscience Research Center (CRN), Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.,Department of Clinical Neuroscience (DNC), Laboratory of Neurotherapies and Neuromodulation, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Sabiha Eddarkaoui
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille, France
| | - Séverine Bégard
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille, France
| | - Catherine Pythoud
- Laboratory of Neurotherapies and Neuromodulation, Neuroscience Research Center (CRN), Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.,Department of Clinical Neuroscience (DNC), Laboratory of Neurotherapies and Neuromodulation, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Maria Rey
- Laboratory of Neurotherapies and Neuromodulation, Neuroscience Research Center (CRN), Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.,Department of Clinical Neuroscience (DNC), Laboratory of Neurotherapies and Neuromodulation, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Raphaëlle Caillierez
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille, France
| | - Kim Q Do
- Department of Psychiatry, Center for Psychiatric Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Sophie Halliez
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille, France
| | - Paola Bezzi
- Department of Fundamental Neurosciences, University of Lausanne, Lausanne, Switzerland
| | - Luc Buée
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille, France
| | - Geneviève Leuba
- Department of Psychiatry, Center for Psychiatric Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Morvane Colin
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille, France
| | - Nicolas Toni
- Department of Psychiatry, Center for Psychiatric Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
| | - Nicole Déglon
- Laboratory of Neurotherapies and Neuromodulation, Neuroscience Research Center (CRN), Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.,Department of Clinical Neuroscience (DNC), Laboratory of Neurotherapies and Neuromodulation, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| |
Collapse
|
12
|
Carracedo S, Loyens A, Eddarkaoui S, Serteyn D, Malo C, Skidmore L, Briand-Amirat L, Barbotin AL, Maurage CA, Delehedde M, Sergeant N. The sperm specific proAKAP4 polypeptide exhibited conserved functions, localizations and metabolism among mammals. Anim Reprod Sci 2020. [DOI: 10.1016/j.anireprosci.2020.106448] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Duriez P, Eddarkaoui S, Blum D, Dickson SL, Gorwood P, Tolle V, Viltart O. Does physical activity associated with chronic food restriction alleviate anxiety like behaviour, in female mice? Horm Behav 2020; 124:104807. [PMID: 32544401 DOI: 10.1016/j.yhbeh.2020.104807] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2020] [Revised: 06/09/2020] [Accepted: 06/10/2020] [Indexed: 12/17/2022]
Abstract
Anorexia nervosa (AN) is an eating disorder characterized by excessive weight loss, persistent food restriction and inappropriate physical activity relative to declining energy balance. The comorbidity with depression and/or anxiety disorders might contribute to the "chronicization" of the disease. We aimed here to question first the link between physical activity and anxiety from a clinical investigation of AN patients (n = 206). Then, using a rodent model mimicking numerous physiological and metabolic alterations commonly seen in AN patients, we examined whether 1) chronic food restriction increased anxiety-like behaviour and 2) physical activity plays a role in regulating anxiety levels. To this end, we exposed young female mice to a chronic food restriction (FR, n = 8) paradigm combined or not with access to a running wheel (FRW, n = 8) for two weeks. The mice were compared to a group of mice fed ad libitum without (AL, n = 6) or with running wheel access (ALW, n = 8). We explored anxiety-like behaviour of all mice in the following tests: hyponeophagia, marble burying, elevated plus maze, open field, and the light and dark box. On the last day, we used a restraint test of 30 min duration and measured their stress reactivity by assaying plasma corticosterone. In the open field and the elevated plus-maze, we found that FRW mice behaved similarly to AL and ALW mice whereas FR mice did not express anxiety-like behaviour. The FRW mice displayed the lowest latency to reach the food in the hyponeophagia test. Regarding stress reactivity, FRW mice exhibited corticosterone reactivity after acute stress that was similar to the control mice, while FR mice did not fully return to basal corticosterone at one hour after the restraint stress. Taken together, these data demonstrate a differential reactivity to acute stress in FR conditions and a beneficial effect of running wheel activity in ALW and FRW conditions. Moreover, we report the absence of a typical anxiety-like behaviour associated with the food restriction (FR and FRW groups). We conclude that this model (FR and FRW mice) did not express typical anxiety-like behaviour, but that physical activity linked to food restriction improved coping strategies in an anxiogenic context.
Collapse
Affiliation(s)
- Philibert Duriez
- Université de Paris, Institute of Psychiatry and Neuroscience of Paris (IPNP) INSERM U1266, "Vulnerability of Psychiatric and Addictive Disorders", F-75014 Paris, France; GHU Paris Psychiatrie et Neurosciences, Hôpital Sainte-Anne, F-75014 Paris, France
| | - Sabiha Eddarkaoui
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France; Alzheimer & Tauopathies, LabEx DISTALZ, LiCEND, F-59000 Lille, France
| | - David Blum
- Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France; Alzheimer & Tauopathies, LabEx DISTALZ, LiCEND, F-59000 Lille, France
| | - Suzanne L Dickson
- Department of Physiology/Endocrine, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, SE-405 30 Gothenburg, Sweden
| | - Philip Gorwood
- Université de Paris, Institute of Psychiatry and Neuroscience of Paris (IPNP) INSERM U1266, "Vulnerability of Psychiatric and Addictive Disorders", F-75014 Paris, France; GHU Paris Psychiatrie et Neurosciences, Hôpital Sainte-Anne, F-75014 Paris, France
| | - Virginie Tolle
- Université de Paris, Institute of Psychiatry and Neuroscience of Paris (IPNP) INSERM U1266, "Vulnerability of Psychiatric and Addictive Disorders", F-75014 Paris, France
| | - Odile Viltart
- Université de Paris, Institute of Psychiatry and Neuroscience of Paris (IPNP) INSERM U1266, "Vulnerability of Psychiatric and Addictive Disorders", F-75014 Paris, France; Université de Lille, F-59650 Villeneuve d'Ascq, France.
| |
Collapse
|
14
|
Carvalho K, Faivre E, Pietrowski MJ, Marques X, Gomez-Murcia V, Deleau A, Huin V, Hansen JN, Kozlov S, Danis C, Temido-Ferreira M, Coelho JE, Mériaux C, Eddarkaoui S, Gras SL, Dumoulin M, Cellai L, Landrieu I, Chern Y, Hamdane M, Buée L, Boutillier AL, Levi S, Halle A, Lopes LV, Blum D. Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor. Brain 2020; 142:3636-3654. [PMID: 31599329 PMCID: PMC6821333 DOI: 10.1093/brain/awz288] [Citation(s) in RCA: 44] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Revised: 07/24/2019] [Accepted: 07/26/2019] [Indexed: 12/14/2022] Open
Abstract
Accumulating data support the role of tau pathology in cognitive decline in ageing and Alzheimer’s disease, but underlying mechanisms remain ill-defined. Interestingly, ageing and Alzheimer’s disease have been associated with an abnormal upregulation of adenosine A2A receptor (A2AR), a fine tuner of synaptic plasticity. However, the link between A2AR signalling and tau pathology has remained largely unexplored. In the present study, we report for the first time a significant upregulation of A2AR in patients suffering from frontotemporal lobar degeneration with the MAPT P301L mutation. To model these alterations, we induced neuronal A2AR upregulation in a tauopathy mouse model (THY-Tau22) using a new conditional strain allowing forebrain overexpression of the receptor. We found that neuronal A2AR upregulation increases tau hyperphosphorylation, potentiating the onset of tau-induced memory deficits. This detrimental effect was linked to a singular microglial signature as revealed by RNA sequencing analysis. In particular, we found that A2AR overexpression in THY-Tau22 mice led to the hippocampal upregulation of C1q complement protein—also observed in patients with frontotemporal lobar degeneration—and correlated with the loss of glutamatergic synapses, likely underlying the observed memory deficits. These data reveal a key impact of overactive neuronal A2AR in the onset of synaptic loss in tauopathies, paving the way for new therapeutic approaches.
Collapse
Affiliation(s)
- Kevin Carvalho
- University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France
| | - Emilie Faivre
- University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France
| | | | - Xavier Marques
- Institut du Fer à Moulin, Inserm UMR-S 1270, Sorbonne Université, F, Paris, France
| | - Victoria Gomez-Murcia
- University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France
| | - Aude Deleau
- University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France
| | - Vincent Huin
- University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France
| | - Jan N Hansen
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
| | - Stanislav Kozlov
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
| | - Clément Danis
- University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France.,University of Lille, CNRS UMR8576, Unité de Glycobiologie Structurale et Fonctionnelle, LabEx DISTALZ, Lille, F Lille, France
| | - Mariana Temido-Ferreira
- Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal
| | - Joana E Coelho
- Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal
| | - Céline Mériaux
- University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France
| | - Sabiha Eddarkaoui
- University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France
| | - Stéphanie Le Gras
- CNRS, Inserm, UMR 7104, GenomEast Platform, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg, F Illkirch, France
| | | | - Lucrezia Cellai
- University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France
| | | | - Isabelle Landrieu
- University of Lille, CNRS UMR8576, Unité de Glycobiologie Structurale et Fonctionnelle, LabEx DISTALZ, Lille, F Lille, France
| | - Yijuang Chern
- Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
| | - Malika Hamdane
- University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France
| | - Luc Buée
- University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France
| | - Anne-Laurence Boutillier
- Laboratoire de Neuroscience Cognitives et Adaptatives (LNCA), CNRS UMR 7364, Université de Strasbourg, F Strasbourg, France
| | - Sabine Levi
- Institut du Fer à Moulin, Inserm UMR-S 1270, Sorbonne Université, F, Paris, France
| | - Annett Halle
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.,Institute of Neuropathology, University of Bonn Medical Center, Bonn, Germany
| | - Luisa V Lopes
- Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal
| | - David Blum
- University of Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, LabEx DISTALZ, F Lille, France
| |
Collapse
|
15
|
Verelst J, Geukens N, Eddarkaoui S, Vliegen D, De Smidt E, Rosseels J, Franssens V, Molenberghs S, Francois C, Stoops E, Bjerke M, Engelborghs S, Laghmouchi M, Carmans S, Buée L, Vanmechelen E, Winderickx J, Thomas D. A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms. Front Mol Biosci 2020; 7:48. [PMID: 32296712 PMCID: PMC7136581 DOI: 10.3389/fmolb.2020.00048] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Accepted: 03/09/2020] [Indexed: 11/30/2022] Open
Abstract
As human Tau undergoes pathologically relevant post-translational modifications when expressed in yeast, the use of humanized yeast models for the generation of novel Tau monoclonal antibodies has previously been proven to be successful. In this study, human Tau2N4R-ΔK280 purified from yeast was used for the immunization of mice and subsequent selection of high affinity Tau-specific monoclonal antibodies. The characterization of four novel antibodies in different Tau model systems yielded a phosphorylation-dependent antibody (15A10), an antibody directed to the first microtubule-binding repeat domain (16B12), a carboxy-terminal antibody (20G10) and an antibody targeting an epitope on the hinge of the first and second amino-terminal insert (18F12). The latter was found to be conformation-dependent, suggesting structural differences between the Tau splicing isoforms and allowing insight in the roles played by the amino-terminal inserts. As this monoclonal antibody also has the capacity to detect tangle-like structures in different transgenic Tau mice and neurofibrillary tangles in brain sections of patients diagnosed with Alzheimer's disease, we also tested the diagnostic potential of 18F12 in a pilot study and found this monoclonal antibody to have the ability to discriminate Alzheimer's disease patients from control individuals based on increased Tau levels in the cerebrospinal fluid.
Collapse
Affiliation(s)
- Joke Verelst
- Functional Biology, KU Leuven, Heverlee, Belgium
| | | | - Sabiha Eddarkaoui
- Univ. Lille, Inserm, CHU-Lille, UMRS1172, Lille Neuroscience & Cognition, LabEx DISTALZ, Alzheimer & Tauopathies, Lille, France
| | | | | | | | | | | | | | | | - Maria Bjerke
- Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Wilrijk, Belgium.,Department of Neurology and Center for Neurosciences, UZ Brussel and Vrije Universtieit Brussel (VUB), Brussels, Belgium
| | - Sebastiaan Engelborghs
- Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Wilrijk, Belgium.,Department of Neurology and Center for Neurosciences, UZ Brussel and Vrije Universtieit Brussel (VUB), Brussels, Belgium
| | | | | | - Luc Buée
- Univ. Lille, Inserm, CHU-Lille, UMRS1172, Lille Neuroscience & Cognition, LabEx DISTALZ, Alzheimer & Tauopathies, Lille, France
| | | | | | | |
Collapse
|
16
|
Jumeau F, Sigala J, Fernandez-Gomez FJ, Eddarkaoui S, Duban-Deweer S, Buée L, Béhal H, Sergeant N, Mitchell V. Correction to: Gel electrophoresis of human sperm: a simple method for evaluating sperm protein quality. Basic Clin Androl 2020; 30:4. [PMID: 32082580 PMCID: PMC7017460 DOI: 10.1186/s12610-020-00102-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Affiliation(s)
- Fanny Jumeau
- 1EA 4308 - GQG - Gametogenesis and gamete quality, University of Lille, F-59000 Lille, France.,2CHU Lille, Reproductive Biology - Spermiology - CECOS Institute, F-59000 Lille, France.,3University of Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, F-59000 Lille, France.,Present address: Reproductive Biology Laboratory - CECOS, Rouen University Hospital, Rouen University, F-76031 Rouen, France
| | - Julien Sigala
- 1EA 4308 - GQG - Gametogenesis and gamete quality, University of Lille, F-59000 Lille, France.,2CHU Lille, Reproductive Biology - Spermiology - CECOS Institute, F-59000 Lille, France.,3University of Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, F-59000 Lille, France
| | - Francisco-Jose Fernandez-Gomez
- 3University of Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, F-59000 Lille, France
| | - Sabiha Eddarkaoui
- 3University of Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, F-59000 Lille, France
| | - Sophie Duban-Deweer
- 4EA 2465 - LBHE Blood-Brain Barrier Laboratory, University of Artois, F-62307 Lens, France
| | - Luc Buée
- 3University of Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, F-59000 Lille, France
| | - Hélène Béhal
- 5CHU Lille, EA 2694 - Santé publique: épidémiologie et qualité des soins, University of Lille, F-59000 Lille, France
| | - Nicolas Sergeant
- 3University of Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, F-59000 Lille, France
| | - Valérie Mitchell
- 1EA 4308 - GQG - Gametogenesis and gamete quality, University of Lille, F-59000 Lille, France.,2CHU Lille, Reproductive Biology - Spermiology - CECOS Institute, F-59000 Lille, France
| |
Collapse
|
17
|
Gary C, Lam S, Hérard AS, Koch JE, Petit F, Gipchtein P, Sawiak SJ, Caillierez R, Eddarkaoui S, Colin M, Aujard F, Deslys JP, Brouillet E, Buée L, Comoy EE, Pifferi F, Picq JL, Dhenain M. Encephalopathy induced by Alzheimer brain inoculation in a non-human primate. Acta Neuropathol Commun 2019; 7:126. [PMID: 31481130 PMCID: PMC6724379 DOI: 10.1186/s40478-019-0771-x] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Accepted: 07/15/2019] [Indexed: 02/28/2023] Open
Abstract
Alzheimer’s disease is characterized by cognitive alterations, cerebral atrophy and neuropathological lesions including neuronal loss, accumulation of misfolded and aggregated β-amyloid peptides (Aβ) and tau proteins. Iatrogenic induction of Aβ is suspected in patients exposed to pituitary-derived hormones, dural grafts, or surgical instruments, presumably contaminated with Aβ. Induction of Aβ and tau lesions has been demonstrated in transgenic mice after contamination with Alzheimer’s disease brain homogenates, with very limited functional consequences. Unlike rodents, primates naturally express Aβ or tau under normal conditions and attempts to transmit Alzheimer pathology to primates have been made for decades. However, none of earlier studies performed any detailed functional assessments. For the first time we demonstrate long term memory and learning impairments in a non-human primate (Microcebus murinus) following intracerebral injections with Alzheimer human brain extracts. Animals inoculated with Alzheimer brain homogenates displayed progressive cognitive impairments (clinical tests assessing cognitive and motor functions), modifications of neuronal activity (detected by electroencephalography), widespread and progressive cerebral atrophy (in vivo MRI assessing cerebral volume loss using automated voxel-based analysis), neuronal loss in the hippocampus and entorhinal cortex (post mortem stereology). They displayed parenchymal and vascular Aβ depositions and tau lesions for some of them, in regions close to the inoculation sites. Although these lesions were sparse, they were never detected in control animals. Tau-positive animals had the lowest performances in a memory task and displayed the greatest neuronal loss. Our study is timely and important as it is the first one to highlight neuronal and clinical dysfunction following inoculation of Alzheimer’s disease brain homogenates in a primate. Clinical signs in a chronic disease such as Alzheimer take a long time to be detectable. Documentation of clinical deterioration and/or dysfunction following intracerebral inoculations with Alzheimer human brain extracts could lead to important new insights about Alzheimer initiation processes.
Collapse
|
18
|
Sergeant N, Vingtdeux V, Eddarkaoui S, Gay M, Evrard C, Le Fur N, Laurent C, Caillierez R, Obriot H, Larchanché PE, Farce A, Coevoet M, Carato P, Kouach M, Descat A, Dallemagne P, Buée-Scherrer V, Blum D, Hamdane M, Buée L, Melnyk P. New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease. Neurobiol Dis 2019; 129:217-233. [PMID: 30928644 DOI: 10.1016/j.nbd.2019.03.028] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2018] [Revised: 03/01/2019] [Accepted: 03/26/2019] [Indexed: 12/01/2022] Open
Abstract
Alzheimer's Disease is a devastating dementing disease involving amyloid deposits, neurofibrillary tangles, progressive and irreversible cognitive impairment. Today, only symptomatic drugs are available and therapeutic treatments, possibly acting at a multiscale level, are thus urgently needed. To that purpose, we designed multi-effects compounds by synthesizing drug candidates derived by substituting a novel N,N'-disubstituted piperazine anti-amyloid scaffold and adding acetylcholinesterase inhibition property. Two compounds were synthesized and evaluated. The most promising hybrid molecule reduces both the amyloid pathology and the Tau pathology as well as the memory impairments in a preclinical model of Alzheimer's disease. In vitro also, the compound reduces the phosphorylation of Tau and inhibits the release of Aβ peptides while preserving the processing of other metabolites of the amyloid precursor protein. We synthetized and tested the first drug capable of ameliorating both the amyloid and Tau pathology in animal models of AD as well as preventing the major brain lesions and associated memory impairments. This work paves the way for future compound medicines against both Alzheimer's-related brain lesions development and the associated cognitive impairments.
Collapse
Affiliation(s)
- Nicolas Sergeant
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France.
| | - Valérie Vingtdeux
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Sabiha Eddarkaoui
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Marion Gay
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Caroline Evrard
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Nicolas Le Fur
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Cyril Laurent
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Raphaelle Caillierez
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Hélène Obriot
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Paul-Emmanuel Larchanché
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Amaury Farce
- Univ. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France
| | - Mathilde Coevoet
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Pascal Carato
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Mostafa Kouach
- Univ. Lille, CUMA - Centre Universitaire de Mesures et d'Analyses, F-59000 Lille, France
| | - Amandine Descat
- Univ. Lille, CUMA - Centre Universitaire de Mesures et d'Analyses, F-59000 Lille, France
| | - Patrick Dallemagne
- UNICAEN, UFR des Sciences Pharmaceutiques, EA 4258 CERMN, F-14032 Caen, France
| | - Valérie Buée-Scherrer
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - David Blum
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Malika Hamdane
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Luc Buée
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Patricia Melnyk
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France.
| |
Collapse
|
19
|
Leboucher A, Ahmed T, Caron E, Tailleux A, Raison S, Joly-Amado A, Marciniak E, Carvalho K, Hamdane M, Bantubungi K, Lancel S, Eddarkaoui S, Caillierez R, Vallez E, Staels B, Vieau D, Balschun D, Buee L, Blum D. Brain insulin response and peripheral metabolic changes in a Tau transgenic mouse model. Neurobiol Dis 2019; 125:14-22. [PMID: 30665005 DOI: 10.1016/j.nbd.2019.01.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2018] [Revised: 12/14/2018] [Accepted: 01/15/2019] [Indexed: 01/01/2023] Open
Abstract
Accumulation of hyper-phosphorylated and aggregated Tau proteins is a neuropathological hallmark of Alzheimer's Disease (AD) and Tauopathies. AD patient brains also exhibit insulin resistance. Whereas, under normal physiological conditions insulin signaling in the brain mediates plasticity and memory formation, it can also regulate peripheral energy homeostasis. Thus, in AD, brain insulin resistance affects both cognitive and metabolic changes described in these patients. While a role of Aβ oligomers and APOE4 towards the development of brain insulin resistance emerged, contribution of Tau pathology has been largely overlooked. Our recent data demonstrated that one of the physiological function of Tau is to sustain brain insulin signaling. We postulated that under pathological conditions, hyper-phosphorylated/aggregated Tau is likely to lose this function and to favor the development of brain insulin resistance. This hypothesis was substantiated by observations from patient brains with pure Tauopathies. To address the potential link between Tau pathology and brain insulin resistance, we have evaluated the brain response to insulin in a transgenic mouse model of AD-like Tau pathology (THY-Tau22). Using electrophysiological and biochemical evaluations, we surprisingly observed that, at a time when Tau pathology and cognitive deficits are overt and obvious, the hippocampus of THY-Tau22 mice exhibits enhanced response to insulin. In addition, we demonstrated that the ability of i.c.v. insulin to promote body weight loss is enhanced in THY-Tau22 mice. In line with this, THY-Tau22 mice exhibited a lower body weight gain, hypoleptinemia and hypoinsulinemia and finally a metabolic resistance to high-fat diet. The present data highlight that the brain of transgenic Tau mice exhibit enhanced brain response to insulin. Whether these observations are ascribed to the development of Tau pathology, and therefore relevant to human Tauopathies, or unexpectedly results from the Tau transgene overexpression is debatable and discussed.
Collapse
Affiliation(s)
- Antoine Leboucher
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, F-59000 Lille, France; LabEx DISTALZ, F-59000 Lille, France
| | - Tariq Ahmed
- Brain & Cognition, Faculty of Psychology & Educational Sciences, KU Leuven, Belgium; Neurological Disorders Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Doha, Qatar
| | - Emilie Caron
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, F-59000 Lille, France
| | - Anne Tailleux
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France
| | - Sylvie Raison
- Institut des Neurosciences Cellulaires et Intégratives, Strasbourg, France
| | - Aurélie Joly-Amado
- Byrd Alzheimer's Institute, Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, USA
| | - Elodie Marciniak
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, F-59000 Lille, France; LabEx DISTALZ, F-59000 Lille, France
| | - Kevin Carvalho
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, F-59000 Lille, France; LabEx DISTALZ, F-59000 Lille, France
| | - Malika Hamdane
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, F-59000 Lille, France; LabEx DISTALZ, F-59000 Lille, France
| | - Kadiombo Bantubungi
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France
| | - Steve Lancel
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France
| | - Sabiha Eddarkaoui
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, F-59000 Lille, France; LabEx DISTALZ, F-59000 Lille, France
| | - Raphaelle Caillierez
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, F-59000 Lille, France; LabEx DISTALZ, F-59000 Lille, France
| | - Emmanuelle Vallez
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France
| | - Bart Staels
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France
| | - Didier Vieau
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, F-59000 Lille, France; LabEx DISTALZ, F-59000 Lille, France
| | - Detlef Balschun
- Brain & Cognition, Faculty of Psychology & Educational Sciences, KU Leuven, Belgium
| | - Luc Buee
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, F-59000 Lille, France; LabEx DISTALZ, F-59000 Lille, France
| | - David Blum
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc, F-59000 Lille, France; LabEx DISTALZ, F-59000 Lille, France.
| |
Collapse
|
20
|
Faivre E, Coelho JE, Zornbach K, Malik E, Baqi Y, Schneider M, Cellai L, Carvalho K, Sebda S, Figeac M, Eddarkaoui S, Caillierez R, Chern Y, Heneka M, Sergeant N, Müller CE, Halle A, Buée L, Lopes LV, Blum D. Beneficial Effect of a Selective Adenosine A 2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer's Disease. Front Mol Neurosci 2018; 11:235. [PMID: 30050407 PMCID: PMC6052540 DOI: 10.3389/fnmol.2018.00235] [Citation(s) in RCA: 62] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2018] [Accepted: 06/15/2018] [Indexed: 02/06/2023] Open
Abstract
Consumption of caffeine, a non-selective adenosine A2A receptor (A2AR) antagonist, reduces the risk of developing Alzheimer’s disease (AD) and mitigates both amyloid and Tau lesions in transgenic mouse models of the disease. While short-term treatment with A2AR antagonists have been shown to alleviate cognitive deficits in mouse models of amyloidogenesis, impact of a chronic and long-term treatment on the development of amyloid burden, associated neuroinflammation and memory deficits has never been assessed. In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A2AR antagonist MSX-3 from 3 to 9-10 months of age. At completion of the treatment, we found that the MSX-3 treatment prevented the development of memory deficits in APP/PS1dE9 mice, without significantly altering hippocampal and cortical gene expressions. Interestingly, MSX-3 treatment led to a significant decrease of Aβ1-42 levels in the cortex of APP/PS1dE9 animals, while Aβ1-40 increased, thereby strongly affecting the Aβ1-42/Aβ1-40 ratio. Together, these data support the idea that A2AR blockade is of therapeutic value for AD.
Collapse
Affiliation(s)
- Emilie Faivre
- Université de Lille, Inserm, CHU-Lille, LabEx DISTALZ, Jean-Pierre Aubert Research Centre UMR-S1172, Alzheimer & Tauopathies, Lille, France
| | - Joana E Coelho
- Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal
| | - Katja Zornbach
- Center of Advanced European Studies and Research, Bonn, Germany
| | - Enas Malik
- PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany
| | - Younis Baqi
- PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany.,Department of Chemistry, Faculty of Science, Sultan Qaboos University, Muscat, Oman
| | - Marion Schneider
- PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany
| | - Lucrezia Cellai
- Université de Lille, Inserm, CHU-Lille, LabEx DISTALZ, Jean-Pierre Aubert Research Centre UMR-S1172, Alzheimer & Tauopathies, Lille, France
| | - Kevin Carvalho
- Université de Lille, Inserm, CHU-Lille, LabEx DISTALZ, Jean-Pierre Aubert Research Centre UMR-S1172, Alzheimer & Tauopathies, Lille, France
| | - Shéhérazade Sebda
- Plateau de Génomique Fonctionnelle et Structurale, CHU Lille, University of Lille, Lille, France
| | - Martin Figeac
- Plateau de Génomique Fonctionnelle et Structurale, CHU Lille, University of Lille, Lille, France
| | - Sabiha Eddarkaoui
- Université de Lille, Inserm, CHU-Lille, LabEx DISTALZ, Jean-Pierre Aubert Research Centre UMR-S1172, Alzheimer & Tauopathies, Lille, France
| | - Raphaëlle Caillierez
- Université de Lille, Inserm, CHU-Lille, LabEx DISTALZ, Jean-Pierre Aubert Research Centre UMR-S1172, Alzheimer & Tauopathies, Lille, France
| | - Yijuang Chern
- Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
| | - Michael Heneka
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.,Department of Neurodegenerative Diseases and Geropsychiatry/Neurology, University of Bonn Medical Center, Bonn, Germany
| | - Nicolas Sergeant
- Université de Lille, Inserm, CHU-Lille, LabEx DISTALZ, Jean-Pierre Aubert Research Centre UMR-S1172, Alzheimer & Tauopathies, Lille, France
| | - Christa E Müller
- PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany
| | - Annett Halle
- Center of Advanced European Studies and Research, Bonn, Germany.,German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
| | - Luc Buée
- Université de Lille, Inserm, CHU-Lille, LabEx DISTALZ, Jean-Pierre Aubert Research Centre UMR-S1172, Alzheimer & Tauopathies, Lille, France
| | - Luisa V Lopes
- Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal
| | - David Blum
- Université de Lille, Inserm, CHU-Lille, LabEx DISTALZ, Jean-Pierre Aubert Research Centre UMR-S1172, Alzheimer & Tauopathies, Lille, France
| |
Collapse
|
21
|
Marciniak E, Leboucher A, Caron E, Ahmed T, Tailleux A, Dumont J, Issad T, Gerhardt E, Pagesy P, Vileno M, Bournonville C, Hamdane M, Bantubungi K, Lancel S, Demeyer D, Eddarkaoui S, Vallez E, Vieau D, Humez S, Faivre E, Grenier-Boley B, Outeiro TF, Staels B, Amouyel P, Balschun D, Buee L, Blum D. Tau deletion promotes brain insulin resistance. J Exp Med 2017; 214:2257-2269. [PMID: 28652303 PMCID: PMC5551570 DOI: 10.1084/jem.20161731] [Citation(s) in RCA: 141] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Revised: 03/20/2017] [Accepted: 05/12/2017] [Indexed: 12/13/2022] Open
Abstract
The molecular pathways underlying tau pathology-induced synaptic/cognitive deficits and neurodegeneration are poorly understood. One prevalent hypothesis is that hyperphosphorylation, misfolding, and fibrillization of tau impair synaptic plasticity and cause degeneration. However, tau pathology may also result in the loss of specific physiological tau functions, which are largely unknown but could contribute to neuronal dysfunction. In the present study, we uncovered a novel function of tau in its ability to regulate brain insulin signaling. We found that tau deletion leads to an impaired hippocampal response to insulin, caused by altered IRS-1 and PTEN (phosphatase and tensin homologue on chromosome 10) activities. Our data also demonstrate that tau knockout mice exhibit an impaired hypothalamic anorexigenic effect of insulin that is associated with energy metabolism alterations. Consistently, we found that tau haplotypes are associated with glycemic traits in humans. The present data have far-reaching clinical implications and raise the hypothesis that pathophysiological tau loss-of-function favors brain insulin resistance, which is instrumental for cognitive and metabolic impairments in Alzheimer's disease patients.
Collapse
Affiliation(s)
- Elodie Marciniak
- Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.,LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France
| | - Antoine Leboucher
- Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.,LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France
| | - Emilie Caron
- Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France
| | - Tariq Ahmed
- Laboratory of Biological Psychology, Faculty of Psychology and Educational Sciences, KU Leuven, Leuven, Belgium.,Neurological Disorders Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Doha, Qatar
| | - Anne Tailleux
- Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011EGID, Lille, France
| | - Julie Dumont
- LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.,Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1167 RID-AGE Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, Lille, France
| | - Tarik Issad
- INSERM U1016, CNRS UMR8104, Université Paris Descartes Sorbonne Paris Cité, Institut Cochin, Paris, France
| | - Ellen Gerhardt
- Department of Experimental Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center Goettingen, Goettingen, Germany
| | - Patrick Pagesy
- INSERM U1016, CNRS UMR8104, Université Paris Descartes Sorbonne Paris Cité, Institut Cochin, Paris, France
| | - Margaux Vileno
- Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.,LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France
| | - Clément Bournonville
- Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.,LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France
| | - Malika Hamdane
- Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.,LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France
| | - Kadiombo Bantubungi
- Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011EGID, Lille, France
| | - Steve Lancel
- Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011EGID, Lille, France
| | - Dominique Demeyer
- Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.,LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France
| | - Sabiha Eddarkaoui
- Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.,LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France
| | - Emmanuelle Vallez
- Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011EGID, Lille, France
| | - Didier Vieau
- Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.,LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France
| | - Sandrine Humez
- Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.,LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France
| | - Emilie Faivre
- Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.,LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France
| | - Benjamin Grenier-Boley
- LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.,Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1167 RID-AGE Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, Lille, France
| | - Tiago F Outeiro
- Department of Experimental Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center Goettingen, Goettingen, Germany
| | - Bart Staels
- Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011EGID, Lille, France
| | - Philippe Amouyel
- LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France.,Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1167 RID-AGE Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, Lille, France
| | - Detlef Balschun
- Laboratory of Biological Psychology, Faculty of Psychology and Educational Sciences, KU Leuven, Leuven, Belgium
| | - Luc Buee
- Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France.,LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France
| | - David Blum
- Université de Lille, Institut National de la Santé et de la Recherche Medicale (INSERM), CHU Lille, UMR-S 1172 JPArc, Lille, France .,LabEx DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Lille, France
| |
Collapse
|
22
|
Papegaey A, Eddarkaoui S, Deramecourt V, Fernandez-Gomez FJ, Pantano P, Obriot H, Machala C, Anquetil V, Camuzat A, Brice A, Maurage CA, Le Ber I, Duyckaerts C, Buée L, Sergeant N, Buée-Scherrer V. Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutation. Acta Neuropathol Commun 2016; 4:74. [PMID: 27435172 PMCID: PMC4952067 DOI: 10.1186/s40478-016-0345-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Accepted: 07/10/2016] [Indexed: 12/12/2022] Open
Abstract
Reduction of Tau protein expression was described in 2003 by Zhukareva et al. in a variant of frontotemporal lobar degeneration (FTLD) referred to as diagnosis of dementia lacking distinctive histopathology, then re-classified as FTLD with ubiquitin inclusions. However, the analysis of Tau expression in FTLD has not been reconsidered since then. Knowledge of the molecular basis of protein aggregates and genes that are mutated in the FTLD spectrum would enable to determine whether the “Tau-less” is a separate pathological entity or if it belongs to an existing subclass of FTLD. To address this question, we have analyzed Tau expression in the frontal brain areas from control, Alzheimer’s disease and FTLD cases, including FTLD- Tau (MAPT), FTLD-TDP (sporadic, FTLD-TDP-GRN, FTLD-TDP-C9ORF72) and sporadic FTLD-FUS, using western blot and 2D-DIGE (Two-Dimensional fluorescence Difference Gel Electrophoresis) approaches. Surprisingly, we found that most of the FTLD-TDP-GRN brains are characterized by a huge reduction of Tau protein expression without any decrease in Tau mRNA levels. Interestingly, only cases affected by point mutations, rather than cases with total deletion of one GRN allele, seem to be affected by this reduction of Tau protein expression. Moreover, proteomic analysis highlighted correlations between reduced Tau protein level, synaptic impairment and massive reactive astrogliosis in these FTLD-GRN cases. Consistent with a recent study, our data also bring new insights regarding the role of progranulin in neurodegeneration by suggesting its involvement in lysosome and synaptic regulation. Together, our results demonstrate a strong association between progranulin deficiency and reduction of Tau protein expression that could lead to severe neuronal and glial dysfunctions. Our study also indicates that this FTLD-TDP-GRN subgroup could be part as a distinct entity of FTLD classification.
Collapse
|
23
|
Gary C, Koch J, Petit F, Hanss Z, Palash AR, Eddarkaoui S, Sawiak S, Herard AS, Deslys JP, Buee L, Comoy E, Picq JL, Pifferi F, Dhenain M. O4‐11‐03: First Demonstration of Functional and Morphological Alterations in Primates after Alzheimer Brain Homogenates Inoculation. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Charlotte Gary
- Centre National de la Recherche Scientifique (CNRS)Fontenay-aux-RosesFrance
- Paris-Saclay UniversityFontenay-aux-RosesFrance
- Commissariat a l Energie Atomique et aux Energies Alternatives (CEA)Fontenay-aux-RosesFrance
| | - James Koch
- Centre National de la Recherche Scientifique (CNRS)Fontenay-aux-RosesFrance
- Paris-Saclay UniversityFontenay-aux-RosesFrance
- Commissariat a l Energie Atomique et aux Energies Alternatives (CEA)Fontenay-aux-RosesFrance
- University of WisconsinOshkoshWI USA
| | - Fanny Petit
- Centre National de la Recherche Scientifique (CNRS)Fontenay-aux-RosesFrance
- Paris-Saclay UniversityFontenay-aux-RosesFrance
- Commissariat a l Energie Atomique et aux Energies Alternatives (CEA)Fontenay-aux-RosesFrance
| | - Zoe Hanss
- Centre National de la Recherche Scientifique (CNRS)Fontenay-aux-RosesFrance
- Paris-Saclay UniversityFontenay-aux-RosesFrance
- Commissariat a l Energie Atomique et aux Energies Alternatives (CEA)Fontenay-aux-RosesFrance
| | | | | | - Stephen Sawiak
- Wolfson Brain Imaging Centre, University of CambridgeCambridgeUnited Kingdom
- Behavioural and Clinical Neuroscience Institute, University of CambridgeCambridgeUnited Kingdom
| | - Anne-Sophie Herard
- Centre National de la Recherche Scientifique (CNRS)Fontenay-aux-RosesFrance
- Paris-Saclay UniversityFontenay-aux-RosesFrance
- Commissariat a l Energie Atomique et aux Energies Alternatives (CEA)Fontenay-aux-RosesFrance
| | - Jean-Philippe Deslys
- Commissariat a l Energie Atomique et aux Energies Alternatives (CEA)Fontenay-aux-RosesFrance
| | - Luc Buee
- Inserm, University of LilleLilleFrance
| | - Emmanuel Comoy
- Commissariat a l Energie Atomique et aux Energies Alternatives (CEA)Fontenay-aux-RosesFrance
| | - Jean-Luc Picq
- Centre National de la Recherche Scientifique (CNRS)Fontenay-aux-RosesFrance
- Paris-Saclay UniversityFontenay-aux-RosesFrance
- Commissariat a l Energie Atomique et aux Energies Alternatives (CEA)Fontenay-aux-RosesFrance
- Paris 8 UniversitySaint-DenisFrance
| | - Fabien Pifferi
- Centre National de la Recherche Scientifique (CNRS)BrunoyFrance
| | - Marc Dhenain
- Centre National de la Recherche Scientifique (CNRS)Fontenay-aux-RosesFrance
- Paris-Saclay UniversityFontenay-aux-RosesFrance
- Commissariat a l Energie Atomique et aux Energies Alternatives (CEA)Fontenay-aux-RosesFrance
| | | |
Collapse
|
24
|
Sergeant N, Jumeau F, Eddarkaoui S, Sigala J, Dossou GF, Delehedde M, Buee L, Yvoz JF, Mitchell V. Investigating proteomic methods and tools to assess sperm quality. Anim Reprod Sci 2016. [DOI: 10.1016/j.anireprosci.2016.03.072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
25
|
Goodwin M, Mohan A, Batra R, Lee KY, Charizanis K, Fernández Gómez FJ, Eddarkaoui S, Sergeant N, Buée L, Kimura T, Clark HB, Dalton J, Takamura K, Weyn-Vanhentenryck SM, Zhang C, Reid T, Ranum LPW, Day JW, Swanson MS. MBNL Sequestration by Toxic RNAs and RNA Misprocessing in the Myotonic Dystrophy Brain. Cell Rep 2015; 12:1159-68. [PMID: 26257173 DOI: 10.1016/j.celrep.2015.07.029] [Citation(s) in RCA: 100] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2015] [Revised: 06/24/2015] [Accepted: 07/14/2015] [Indexed: 11/19/2022] Open
Abstract
For some neurological disorders, disease is primarily RNA mediated due to expression of non-coding microsatellite expansion RNAs (RNA(exp)). Toxicity is thought to result from enhanced binding of proteins to these expansions and depletion from their normal cellular targets. However, experimental evidence for this sequestration model is lacking. Here, we use HITS-CLIP and pre-mRNA processing analysis of human control versus myotonic dystrophy (DM) brains to provide compelling evidence for this RNA toxicity model. MBNL2 binds directly to DM repeat expansions in the brain, resulting in depletion from its normal RNA targets with downstream effects on alternative splicing and polyadenylation. Similar RNA processing defects were detected in Mbnl compound-knockout mice, highlighted by dysregulation of Mapt splicing and fetal tau isoform expression in adults. These results demonstrate that MBNL proteins are directly sequestered by RNA(exp) in the DM brain and introduce a powerful experimental tool to evaluate RNA-mediated toxicity in other expansion diseases.
Collapse
Affiliation(s)
- Marianne Goodwin
- Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of Medicine, Gainesville, FL 32610, USA
| | - Apoorva Mohan
- Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of Medicine, Gainesville, FL 32610, USA
| | - Ranjan Batra
- Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of Medicine, Gainesville, FL 32610, USA
| | - Kuang-Yung Lee
- Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of Medicine, Gainesville, FL 32610, USA; Department of Neurology, Chang Gung Memorial Hospital, Keelung 20401, Taiwan
| | - Konstantinos Charizanis
- Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of Medicine, Gainesville, FL 32610, USA; InSiliGen LLC, Gainesville, FL 32606, USA
| | - Francisco José Fernández Gómez
- Inserm UMR S1172, Alzheimer and Tauopathies, Université Lille Nord de France, Centre Jean-Pierre Aubert, 1 Place Verdun, 59045 Lille, France
| | - Sabiha Eddarkaoui
- Inserm UMR S1172, Alzheimer and Tauopathies, Université Lille Nord de France, Centre Jean-Pierre Aubert, 1 Place Verdun, 59045 Lille, France
| | - Nicolas Sergeant
- Inserm UMR S1172, Alzheimer and Tauopathies, Université Lille Nord de France, Centre Jean-Pierre Aubert, 1 Place Verdun, 59045 Lille, France
| | - Luc Buée
- Inserm UMR S1172, Alzheimer and Tauopathies, Université Lille Nord de France, Centre Jean-Pierre Aubert, 1 Place Verdun, 59045 Lille, France
| | - Takashi Kimura
- Division of Neurology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo 663-8501, Japan
| | - H Brent Clark
- Departments of Laboratory Medicine and Pathology, Neurology, Neurosurgery, and Genetics, Cell Biology, and Development, University of Minnesota Medical School, Minneapolis, MN 55455, USA
| | - Joline Dalton
- Departments of Laboratory Medicine and Pathology, Neurology, Neurosurgery, and Genetics, Cell Biology, and Development, University of Minnesota Medical School, Minneapolis, MN 55455, USA
| | - Kenji Takamura
- Departments of Laboratory Medicine and Pathology, Neurology, Neurosurgery, and Genetics, Cell Biology, and Development, University of Minnesota Medical School, Minneapolis, MN 55455, USA
| | - Sebastien M Weyn-Vanhentenryck
- Department of Systems Biology, Department of Biochemistry and Molecular Biophysics, Center for Motor Neuron Biology and Disease, Columbia University, New York, NY 10032, USA
| | - Chaolin Zhang
- Department of Systems Biology, Department of Biochemistry and Molecular Biophysics, Center for Motor Neuron Biology and Disease, Columbia University, New York, NY 10032, USA
| | - Tammy Reid
- Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of Medicine, Gainesville, FL 32610, USA
| | - Laura P W Ranum
- Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of Medicine, Gainesville, FL 32610, USA
| | - John W Day
- Department of Neurology and Neurological Sciences, School of Medicine, Stanford University, Palo Alto, CA 94305, USA
| | - Maurice S Swanson
- Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, University of Florida, College of Medicine, Gainesville, FL 32610, USA.
| |
Collapse
|
26
|
Melnyk P, Vingtdeux V, Burlet S, Eddarkaoui S, Grosjean ME, Larchanché PE, Hochart G, Sergheraert C, Estrella C, Barrier M, Poix V, Plancq P, Lannoo C, Hamdane M, Delacourte A, Verwaerde P, Buée L, Sergeant N. Chloroquine and chloroquinoline derivatives as models for the design of modulators of amyloid Peptide precursor metabolism. ACS Chem Neurosci 2015; 6:559-69. [PMID: 25611616 DOI: 10.1021/cn5003013] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
The amyloid precursor protein (APP) plays a central role in Alzheimer's disease (AD). Preventing deregulated APP processing by inhibiting amyloidogenic processing of carboxy-terminal fragments (APP-CTFs), and reducing the toxic effect of amyloid beta (Aβ) peptides remain an effective therapeutic strategy. We report the design of piperazine-containing compounds derived from chloroquine structure and evaluation of their effects on APP metabolism and ability to modulate the processing of APP-CTF and the production of Aβ peptide. Compounds which retained alkaline properties and high affinity for acidic cell compartments were the most effective. The present study demonstrates that (1) the amino side chain of chloroquine can be efficiently substituted by a bis(alkylamino)piperazine chain, (2) the quinoline nucleus can be replaced by a benzyl or a benzimidazole moiety, and (3) pharmacomodulation of the chemical structure allows the redirection of APP metabolism toward a decrease of Aβ peptide release, and increased stability of APP-CTFs and amyloid intracellular fragment. Moreover, the benzimidazole compound 29 increases APP-CTFs in vivo and shows promising activity by the oral route. Together, this family of compounds retains a lysosomotropic activity which inhibits lysosome-related Aβ production, and is likely to be beneficial for therapeutic applications in AD.
Collapse
Affiliation(s)
- Patricia Melnyk
- Université de Lille, F-59000 Lille, France
- UDSL, EA 4481,
UFR Pharmacie, F-59000 Lille, France
- CNRS UMR8161, F-59000 Lille, France
| | - Valérie Vingtdeux
- Université de Lille, F-59000 Lille, France
- Inserm UMR-S1172, Alzheimer & Tauopathies, Jean-Pierre Aubert Research Center, F-59000 Lille, France
| | | | - Sabiha Eddarkaoui
- Université de Lille, F-59000 Lille, France
- Inserm UMR-S1172, Alzheimer & Tauopathies, Jean-Pierre Aubert Research Center, F-59000 Lille, France
| | - Marie-Eve Grosjean
- Université de Lille, F-59000 Lille, France
- Inserm UMR-S1172, Alzheimer & Tauopathies, Jean-Pierre Aubert Research Center, F-59000 Lille, France
| | | | - Guillaume Hochart
- Université de Lille, F-59000 Lille, France
- UDSL, EA 4481,
UFR Pharmacie, F-59000 Lille, France
- CNRS UMR8161, F-59000 Lille, France
| | | | | | | | | | | | | | - Malika Hamdane
- Université de Lille, F-59000 Lille, France
- Inserm UMR-S1172, Alzheimer & Tauopathies, Jean-Pierre Aubert Research Center, F-59000 Lille, France
| | - André Delacourte
- Université de Lille, F-59000 Lille, France
- Inserm UMR-S1172, Alzheimer & Tauopathies, Jean-Pierre Aubert Research Center, F-59000 Lille, France
| | | | - Luc Buée
- Université de Lille, F-59000 Lille, France
- Inserm UMR-S1172, Alzheimer & Tauopathies, Jean-Pierre Aubert Research Center, F-59000 Lille, France
| | - Nicolas Sergeant
- Université de Lille, F-59000 Lille, France
- Inserm UMR-S1172, Alzheimer & Tauopathies, Jean-Pierre Aubert Research Center, F-59000 Lille, France
| |
Collapse
|
27
|
Fernandez-Gomez FJ, Jumeau F, Derisbourg M, Burnouf S, Tran H, Eddarkaoui S, Obriot H, Dutoit-Lefevre V, Deramecourt V, Mitchell V, Lefranc D, Hamdane M, Blum D, Buée L, Buée-Scherrer V, Sergeant N. Consensus brain-derived protein, extraction protocol for the study of human and murine brain proteome using both 2D-DIGE and mini 2DE immunoblotting. J Vis Exp 2014. [PMID: 24747743 DOI: 10.3791/51339] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Two-dimensional gel electrophoresis (2DE) is a powerful tool to uncover proteome modifications potentially related to different physiological or pathological conditions. Basically, this technique is based on the separation of proteins according to their isoelectric point in a first step, and secondly according to their molecular weights by SDS polyacrylamide gel electrophoresis (SDS-PAGE). In this report an optimized sample preparation protocol for little amount of human post-mortem and mouse brain tissue is described. This method enables to perform both two-dimensional fluorescence difference gel electrophoresis (2D-DIGE) and mini 2DE immunoblotting. The combination of these approaches allows one to not only find new proteins and/or protein modifications in their expression thanks to its compatibility with mass spectrometry detection, but also a new insight into markers validation. Thus, mini-2DE coupled to western blotting permits to identify and validate post-translational modifications, proteins catabolism and provides a qualitative comparison among different conditions and/or treatments. Herein, we provide a method to study components of protein aggregates found in AD and Lewy body dementia such as the amyloid-beta peptide and the alpha-synuclein. Our method can thus be adapted for the analysis of the proteome and insoluble proteins extract from human brain tissue and mice models too. In parallel, it may provide useful information for the study of molecular and cellular pathways involved in neurodegenerative diseases as well as potential novel biomarkers and therapeutic targets.
Collapse
Affiliation(s)
| | - Fanny Jumeau
- Team Alzheimer & Tauopathies, Jean-Pierre Aubert Research Centre, Inserm UMR 837; EA 4308-Department of Reproductive Biology-Spermiology-CECOS, CHRU-Lille
| | - Maxime Derisbourg
- Team Alzheimer & Tauopathies, Jean-Pierre Aubert Research Centre, Inserm UMR 837
| | - Sylvie Burnouf
- Team Alzheimer & Tauopathies, Jean-Pierre Aubert Research Centre, Inserm UMR 837
| | - Hélène Tran
- Team Alzheimer & Tauopathies, Jean-Pierre Aubert Research Centre, Inserm UMR 837
| | - Sabiha Eddarkaoui
- Team Alzheimer & Tauopathies, Jean-Pierre Aubert Research Centre, Inserm UMR 837
| | - Hélène Obriot
- Team Alzheimer & Tauopathies, Jean-Pierre Aubert Research Centre, Inserm UMR 837
| | | | | | - Valérie Mitchell
- EA 4308-Department of Reproductive Biology-Spermiology-CECOS, CHRU-Lille
| | - Didier Lefranc
- EA2686-Laboratorie d'Immunologie, Faculté de Médecine - Pôle Recherche
| | - Malika Hamdane
- Team Alzheimer & Tauopathies, Jean-Pierre Aubert Research Centre, Inserm UMR 837
| | - David Blum
- Team Alzheimer & Tauopathies, Jean-Pierre Aubert Research Centre, Inserm UMR 837
| | - Luc Buée
- Team Alzheimer & Tauopathies, Jean-Pierre Aubert Research Centre, Inserm UMR 837
| | | | - Nicolas Sergeant
- Team Alzheimer & Tauopathies, Jean-Pierre Aubert Research Centre, Inserm UMR 837;
| |
Collapse
|
28
|
Carpentier C, Ghanem D, Fernandez-Gomez FJ, Jumeau F, Philippe JV, Freyermuth F, Labudeck A, Eddarkaoui S, Dhaenens CM, Holt I, Behm-Ansmant I, Marmier-Gourrier N, Branlant C, Charlet-Berguerand N, Marie J, Schraen-Maschke S, Buée L, Sergeant N, Caillet-Boudin ML. Tau exon 2 responsive elements deregulated in myotonic dystrophy type I are proximal to exon 2 and synergistically regulated by MBNL1 and MBNL2. Biochim Biophys Acta Mol Basis Dis 2014; 1842:654-64. [PMID: 24440524 DOI: 10.1016/j.bbadis.2014.01.004] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2013] [Revised: 12/09/2013] [Accepted: 01/07/2014] [Indexed: 01/21/2023]
Abstract
The splicing of the microtubule-associated protein Tau is regulated during development and is found to be deregulated in a growing number of pathological conditions such as myotonic dystrophy type I (DM1), in which a reduced number of isoforms is expressed in the adult brain. DM1 is caused by a dynamic and unstable CTG repeat expansion in the DMPK gene, resulting in an RNA bearing long CUG repeats (n>50) that accumulates in nuclear foci and sequesters CUG-binding splicing factors of the muscle blind-like (MBNL) family, involved in the splicing of Tau pre-mRNA among others. However, the precise mechanism leading to Tau mis-splicing and the role of MBNL splicing factors in this process are poorly understood. We therefore used new Tau minigenes that we developed for this purpose to determine how MBNL1 and MBNL2 interact to regulate Tau exon 2 splicing. We demonstrate that an intronic region 250 nucleotides downstream of Tau exon 2 contains cis-regulatory splicing enhancers that are sensitive to MBNL and that bind directly to MBNL1. Both MBNL1 and MBNL2 act as enhancers of Tau exon 2 inclusion. Intriguingly, the interaction of MBNL1 and MBNL2 is required to fully reverse the mis-splicing of Tau exon 2 induced by the trans-dominant effect of long CUG repeats, similar to the DM1 condition. In conclusion, both MBNL1 and MBNL2 are involved in the regulation of Tau exon 2 splicing and the mis-splicing of Tau in DM1 is due to the combined inactivation of both.
Collapse
Affiliation(s)
- C Carpentier
- Inserm UMR837-1 and Univ. Lille Nord de France, Jean-Pierre Aubert Research Center, Alzheimer & Tauopathies, F-59045 Lille, France; Regional University Hospital of Lille, France
| | - D Ghanem
- Inserm UMR837-1 and Univ. Lille Nord de France, Jean-Pierre Aubert Research Center, Alzheimer & Tauopathies, F-59045 Lille, France; Regional University Hospital of Lille, France
| | - F J Fernandez-Gomez
- Inserm UMR837-1 and Univ. Lille Nord de France, Jean-Pierre Aubert Research Center, Alzheimer & Tauopathies, F-59045 Lille, France; Regional University Hospital of Lille, France
| | - F Jumeau
- Inserm UMR837-1 and Univ. Lille Nord de France, Jean-Pierre Aubert Research Center, Alzheimer & Tauopathies, F-59045 Lille, France; Regional University Hospital of Lille, France
| | - J V Philippe
- Laboratory of Molecular Engineering and Articular Pathophysiology (IMoPA), Nancy University - CNRS, UMR 7214, 7365 Vandoeuvre-les-Nancy, France
| | - F Freyermuth
- Department de Neurobiology & Genetics, IGBMC, Inserm U964, CNRS UMR7104, University of Strasbourg, Illkirch, France
| | - A Labudeck
- Inserm UMR837-1 and Univ. Lille Nord de France, Jean-Pierre Aubert Research Center, Alzheimer & Tauopathies, F-59045 Lille, France; Regional University Hospital of Lille, France
| | - S Eddarkaoui
- Inserm UMR837-1 and Univ. Lille Nord de France, Jean-Pierre Aubert Research Center, Alzheimer & Tauopathies, F-59045 Lille, France; Regional University Hospital of Lille, France
| | - C M Dhaenens
- Inserm UMR837-1 and Univ. Lille Nord de France, Jean-Pierre Aubert Research Center, Alzheimer & Tauopathies, F-59045 Lille, France; Regional University Hospital of Lille, France
| | - I Holt
- Wolfson Centre for Inherited Neuromuscular Disease, RJAH Orthopaedic Hospital, Oswestry, Shropshire, UK; Institute for Science and Technology in Medicine, Keele University, Keele, Staffordshire, UK
| | - I Behm-Ansmant
- Laboratory of Molecular Engineering and Articular Pathophysiology (IMoPA), Nancy University - CNRS, UMR 7214, 7365 Vandoeuvre-les-Nancy, France
| | - N Marmier-Gourrier
- Laboratory of Molecular Engineering and Articular Pathophysiology (IMoPA), Nancy University - CNRS, UMR 7214, 7365 Vandoeuvre-les-Nancy, France
| | - C Branlant
- Laboratory of Molecular Engineering and Articular Pathophysiology (IMoPA), Nancy University - CNRS, UMR 7214, 7365 Vandoeuvre-les-Nancy, France
| | - N Charlet-Berguerand
- Department de Neurobiology & Genetics, IGBMC, Inserm U964, CNRS UMR7104, University of Strasbourg, Illkirch, France
| | - J Marie
- Therapy of muscular diseases - Myology Institute, UPMC Univ. Paris 6, UM76/Inserm, U974/CNRS, UMR 7215, G.H. Pitié-Salpétrière - Bâtiment Babinski, Paris, France
| | - S Schraen-Maschke
- Inserm UMR837-1 and Univ. Lille Nord de France, Jean-Pierre Aubert Research Center, Alzheimer & Tauopathies, F-59045 Lille, France; Regional University Hospital of Lille, France
| | - L Buée
- Inserm UMR837-1 and Univ. Lille Nord de France, Jean-Pierre Aubert Research Center, Alzheimer & Tauopathies, F-59045 Lille, France; Regional University Hospital of Lille, France
| | - N Sergeant
- Inserm UMR837-1 and Univ. Lille Nord de France, Jean-Pierre Aubert Research Center, Alzheimer & Tauopathies, F-59045 Lille, France; Regional University Hospital of Lille, France.
| | - M L Caillet-Boudin
- Inserm UMR837-1 and Univ. Lille Nord de France, Jean-Pierre Aubert Research Center, Alzheimer & Tauopathies, F-59045 Lille, France; Regional University Hospital of Lille, France.
| |
Collapse
|
29
|
Leboucher A, Laurent C, Fernandez-Gomez FJ, Burnouf S, Troquier L, Eddarkaoui S, Demeyer D, Caillierez R, Zommer N, Vallez E, Bantubungi K, Breton C, Pigny P, Buée-Scherrer V, Staels B, Hamdane M, Tailleux A, Buée L, Blum D. Detrimental effects of diet-induced obesity on τ pathology are independent of insulin resistance in τ transgenic mice. Diabetes 2013; 62:1681-8. [PMID: 23250356 PMCID: PMC3636620 DOI: 10.2337/db12-0866] [Citation(s) in RCA: 83] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The τ pathology found in Alzheimer disease (AD) is crucial in cognitive decline. Midlife development of obesity, a major risk factor of insulin resistance and type 2 diabetes, increases the risk of dementia and AD later in life. The impact of obesity on AD risk has been suggested to be related to central insulin resistance, secondary to peripheral insulin resistance. The effects of diet-induced obesity (DIO) on τ pathology remain unknown. In this study, we evaluated effects of a high-fat diet, given at an early pathological stage, in the THY-Tau22 transgenic mouse model of progressive AD-like τ pathology. We found that early and progressive obesity potentiated spatial learning deficits as well as hippocampal τ pathology at a later stage. Surprisingly, THY-Tau22 mice did not exhibit peripheral insulin resistance. Further, pathological worsening occurred while hippocampal insulin signaling was upregulated. Together, our data demonstrate that DIO worsens τ phosphorylation and learning abilities in τ transgenic mice independently from peripheral/central insulin resistance.
Collapse
Affiliation(s)
- Antoine Leboucher
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U837, Jean-Pierre Aubert Research Centre, Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France
| | - Cyril Laurent
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U837, Jean-Pierre Aubert Research Centre, Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France
| | - Francisco-José Fernandez-Gomez
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U837, Jean-Pierre Aubert Research Centre, Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France
| | - Sylvie Burnouf
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U837, Jean-Pierre Aubert Research Centre, Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France
| | - Laetitia Troquier
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U837, Jean-Pierre Aubert Research Centre, Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France
| | - Sabiha Eddarkaoui
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U837, Jean-Pierre Aubert Research Centre, Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France
| | - Dominique Demeyer
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U837, Jean-Pierre Aubert Research Centre, Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France
| | - Raphaëlle Caillierez
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U837, Jean-Pierre Aubert Research Centre, Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France
| | - Nadège Zommer
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U837, Jean-Pierre Aubert Research Centre, Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France
| | - Emmanuelle Vallez
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U1011, Lille, France
- Institut Pasteur de Lille, Lille, France
| | - Kadiombo Bantubungi
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U1011, Lille, France
- Institut Pasteur de Lille, Lille, France
| | - Christophe Breton
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- EA 4489, Environnement Perinatal et Croissance, Lille, France
| | - Pascal Pigny
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U837, Jean-Pierre Aubert Research Centre, Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France
- Centre Hospitalier Régional Universitaire de Lille, Lille, France
| | - Valérie Buée-Scherrer
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U837, Jean-Pierre Aubert Research Centre, Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France
| | - Bart Staels
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U1011, Lille, France
- Institut Pasteur de Lille, Lille, France
| | - Malika Hamdane
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U837, Jean-Pierre Aubert Research Centre, Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France
| | - Anne Tailleux
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U1011, Lille, France
- Institut Pasteur de Lille, Lille, France
| | - Luc Buée
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U837, Jean-Pierre Aubert Research Centre, Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France
- Centre Hospitalier Régional Universitaire de Lille, Lille, France
| | - David Blum
- Université Lille-Nord de France, Université du Droit et de la Santé de Lille, Lille, France
- INSERM U837, Jean-Pierre Aubert Research Centre, Institut de Médecine Prédictive et de Recherche Thérapeutique, Lille, France
- Centre Hospitalier Régional Universitaire de Lille, Lille, France
- Corresponding author: David Blum,
| |
Collapse
|
30
|
Van der Jeugd A, Blum D, Raison S, Eddarkaoui S, Bue L, DHooge R. Observations in THY-Tau22 mice that resemble behavioral and psychological signs and symptoms of dementia. Behav Brain Res 2013; 242:34-9. [DOI: 10.1016/j.bbr.2012.12.008] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2012] [Revised: 11/27/2012] [Accepted: 12/05/2012] [Indexed: 01/16/2023]
|
31
|
Burnouf S, Martire A, Derisbourg M, Laurent C, Belarbi K, Leboucher A, Fernandez-Gomez FJ, Troquier L, Eddarkaoui S, Grosjean ME, Demeyer D, Muhr-Tailleux A, Buisson A, Sergeant N, Hamdane M, Humez S, Popoli P, Buée L, Blum D. NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model. Aging Cell 2013; 12:11-23. [PMID: 23082852 DOI: 10.1111/acel.12018] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/20/2012] [Indexed: 12/24/2022] Open
Abstract
While the spatiotemporal development of Tau pathology has been correlated with occurrence of cognitive deficits in Alzheimer's patients, mechanisms underlying these deficits remain unclear. Both brain-derived neurotrophic factor (BDNF) and its tyrosine kinase receptor TrkB play a critical role in hippocampus-dependent synaptic plasticity and memory. When applied on hippocampal slices, BDNF is able to enhance AMPA receptor-dependent hippocampal basal synaptic transmission through a mechanism involving TrkB and N-methyl-d-Aspartate receptors (NMDAR). Using THY-Tau22 transgenic mice, we demonstrated that hippocampal Tau pathology is associated with loss of synaptic enhancement normally induced by exogenous BDNF. This defective response was concomitant to significant memory impairments. We show here that loss of BDNF response was due to impaired NMDAR function. Indeed, we observed a significant reduction of NMDA-induced field excitatory postsynaptic potential depression in the hippocampus of Tau mice together with a reduced phosphorylation of NR2B at the Y1472, known to be critical for NMDAR function. Interestingly, we found that both NR2B and Src, one of the NR2B main kinases, interact with Tau and are mislocalized to the insoluble protein fraction rich in pathological Tau species. Defective response to BDNF was thus likely related to abnormal interaction of Src and NR2B with Tau in THY-Tau22 animals. These are the first data demonstrating a relationship between Tau pathology and synaptic effects of BDNF and supporting a contribution of defective BDNF response and impaired NMDAR function to the cognitive deficits associated with Tauopathies.
Collapse
Affiliation(s)
| | - Alberto Martire
- Department of Therapeutic Research and Medicine Evaluation; Istituto Superiore di Sanità; I-00161; Rome; Italy
| | | | | | | | | | | | | | | | | | | | | | - Alain Buisson
- Grenoble Institute Neurosciences; U836 INSERM; Université J. Fourier; 38042; Grenoble; France
| | | | | | | | - Patrizia Popoli
- Department of Therapeutic Research and Medicine Evaluation; Istituto Superiore di Sanità; I-00161; Rome; Italy
| | | | | |
Collapse
|
32
|
Caillet‐Boudin M, Dhaenens C, Frandemiche M, Tran H, Carpentier C, Fernandez‐Gomez F, Sistiaga A, Goicoechea M, Van Brussel E, Obriot H, Eddarkaoui S, Gavaert M, Sablonniere B, Lopez‐de‐munain A, Buee L, Schraen S, Sergeant N. P3‐120: Mis‐splicing of Tau Exon 2 and Exon 10 in myotonic dystrophy brain would result from different mechanisms. Alzheimers Dement 2011. [DOI: 10.1016/j.jalz.2011.05.1561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
| | - Claire‐Marie Dhaenens
- Inserm, U837‐1Univ. Lille Nord de France, IMPRT, Centre Jean‐Pierre Aubert, LilleFranceLilleFrance
| | - Marie‐Lise Frandemiche
- Inserm, U837‐1Univ. Lille Nord de France, IMPRT, Centre Jean‐Pierre Aubert, LilleFranceLilleFrance
| | - Helene Tran
- Inserm, U837‐1Univ. Lille Nord de France, IMPRT, Centre Jean‐Pierre Aubert, LilleFranceLilleFrance
| | - Celine Carpentier
- Inserm, U837‐1Univ. Lille Nord de France, IMPRT, Centre Jean‐Pierre Aubert, LilleFranceLilleFrance
| | | | - Andone Sistiaga
- Neurological Department and Experimental UnitDonostia Hospital, San SebastianSpainSan SebastianSpain
| | - Maria Goicoechea
- Neurological Department and Experimental UnitDonostia Hospital, San SebastianSpainSan SebastianSpain
| | - Edwige Van Brussel
- Inserm, U837‐1Univ. Lille Nord de France, IMPRT, Centre Jean‐Pierre Aubert, LilleFranceLilleFrance
| | - Helene Obriot
- Inserm, U837‐1Univ. Lille Nord de France, IMPRT, Centre Jean‐Pierre Aubert, LilleFranceLilleFrance
| | - Sabiha Eddarkaoui
- Inserm, U837‐1Univ. Lille Nord de France, IMPRT, Centre Jean‐Pierre Aubert, LilleFranceLilleFrance
| | - Marie‐Helene Gavaert
- Neuropathological DepartmentRegional University Hospital Centre, LilleFrance.LilleFrance
| | - Bernard Sablonniere
- Inserm, U837‐1Univ. Lille Nord de France, IMPRT, Centre Jean‐Pierre Aubert, LilleFranceLilleFrance
| | - Adolfo Lopez‐de‐munain
- Neurological Department and Experimental UnitDonostia Hospital, San SebastianSpainLilleFrance
| | | | - Susanna Schraen
- Inserm, U837‐1Univ. Lille Nord de France, IMPRT, Centre Jean‐Pierre Aubert, LilleFranceLilleFrance
| | - Nicolas Sergeant
- Inserm, U837‐1Univ. Lille Nord de France, IMPRT, Centre Jean‐Pierre Aubert, LilleFranceLilleFrance
| |
Collapse
|
33
|
Dhaenens CM, Tran H, Frandemiche ML, Carpentier C, Schraen-Maschke S, Sistiaga A, Goicoechea M, Eddarkaoui S, Van Brussels E, Obriot H, Labudeck A, Gevaert MH, Fernandez-Gomez F, Charlet-Berguerand N, Deramecourt V, Maurage CA, Buée L, Lopez de Munain A, Sablonnière B, Caillet-Boudin ML, Sergeant N. Mis-splicing of Tau exon 10 in myotonic dystrophy type 1 is reproduced by overexpression of CELF2 but not by MBNL1 silencing. Biochim Biophys Acta Mol Basis Dis 2011; 1812:732-42. [PMID: 21439371 DOI: 10.1016/j.bbadis.2011.03.010] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2010] [Revised: 03/16/2011] [Accepted: 03/17/2011] [Indexed: 12/13/2022]
Abstract
Tau is the proteinaceous component of intraneuronal aggregates common to neurodegenerative diseases called Tauopathies, including myotonic dystrophy type 1. In myotonic dystrophy type 1, the presence of microtubule-associated protein Tau aggregates is associated with a mis-splicing of Tau. A toxic gain-of-function at the ribonucleic acid level is a major etiological factor responsible for the mis-splicing of several transcripts in myotonic dystrophy type 1. These are probably the consequence of a loss of muscleblind-like 1 (MBNL1) function or gain of CUGBP1 and ETR3-like factor 1 (CELF1) splicing function. Whether these two dysfunctions occur together or separately and whether all mis-splicing events in myotonic dystrophy type 1 brain result from one or both of these dysfunctions remains unknown. Here, we analyzed the splicing of Tau exons 2 and 10 in the brain of myotonic dystrophy type 1 patients. Two myotonic dystrophy type 1 patients showed a mis-splicing of exon 10 whereas exon 2-inclusion was reduced in all myotonic dystrophy type 1 patients. In order to determine the potential factors responsible for exon 10 mis-splicing, we studied the effect of the splicing factors muscleblind-like 1 (MBNL1), CUGBP1 and ETR3-like factor 1 (CELF1), CUGBP1 and ETR3-like factor 2 (CELF2), and CUGBP1 and ETR3-like factor 4 (CELF4) or a dominant-negative CUGBP1 and ETR-3 like factor (CELF) factor on Tau exon 10 splicing by ectopic expression or siRNA. Interestingly, the inclusion of Tau exon 10 is reduced by CUGBP1 and ETR3-like factor 2 (CELF2) whereas it is insensitive to the loss-of-function of muscleblind-like 1 (MBNL1), CUGBP1 and ETR3-like factor 1 (CELF1) gain-of-function, or a dominant-negative of CUGBP1 and ETR-3 like factor (CELF) factor. Moreover, we observed an increased expression of CUGBP1 and ETR3-like factor 2 (CELF2) only in the brain of myotonic dystrophy type 1 patients with a mis-splicing of exon 10. Taken together, our results indicate the occurrence of a mis-splicing event in myotonic dystrophy type 1 that is induced neither by a loss of muscleblind-like 1 (MBNL1) function nor by a gain of CUGBP1 and ETR3-like factor 1 (CELF1) function but is rather associated to CUGBP1 and ETR3-like factor 2 (CELF2) gain-of-function.
Collapse
Affiliation(s)
- C M Dhaenens
- Inserm, U837-1, Alzheimer & Tauopathies, place de Verdun, F-59045 Lille, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Tran H, Gourrier N, Lemercier-Neuillet C, Dhaenens CM, Vautrin A, Fernandez-Gomez FJ, Arandel L, Carpentier C, Obriot H, Eddarkaoui S, Delattre L, Van Brussels E, Holt I, Morris GE, Sablonnière B, Buée L, Charlet-Berguerand N, Schraen-Maschke S, Furling D, Behm-Ansmant I, Branlant C, Caillet-Boudin ML, Sergeant N. Analysis of exonic regions involved in nuclear localization, splicing activity, and dimerization of Muscleblind-like-1 isoforms. J Biol Chem 2011; 286:16435-46. [PMID: 21454535 DOI: 10.1074/jbc.m110.194928] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Muscleblind-like-1 (MBNL1) is a splicing regulatory factor controlling the fetal-to-adult alternative splicing transitions during vertebrate muscle development. Its capture by nuclear CUG expansions is one major cause for type 1 myotonic dystrophy (DM1). Alternative splicing produces MBNL1 isoforms that differ by the presence or absence of the exonic regions 3, 5, and 7. To understand better their respective roles and the consequences of the deregulation of their expression in DM1, here we studied the respective roles of MBNL1 alternative and constitutive exons. By combining genetics, molecular and cellular approaches, we found that (i) the exon 5 and 6 regions are both needed to control the nuclear localization of MBNL1; (ii) the exon 3 region strongly enhances the affinity of MBNL1 for its pre-mRNA target sites; (iii) the exon 3 and 6 regions are both required for the splicing regulatory activity, and this function is not enhanced by an exclusive nuclear localization of MBNL1; and finally (iv) the exon 7 region enhances MBNL1-MBNL1 dimerization properties. Consequently, the abnormally high inclusion of the exon 5 and 7 regions in DM1 is expected to enhance the potential of MBNL1 of being sequestered with nuclear CUG expansions, which provides new insight into DM1 pathophysiology.
Collapse
Affiliation(s)
- Hélène Tran
- INSERM, U837, Alzheimer and Tauopathies, Lille, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|